Full Year 2014 Presentation with appendix
Roche 2014 results London, 28 January 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 2 3 4 5 6 7 8 9 10 11 pricing and product initiatives of competitors; legislative and regulatory developments and economic conditions; delay or inability in obtaining regulatory approvals or bringing products to market; fluctuations in currency exchange rates and general financial market conditions; uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; increased government pricing pressures; interruptions in production; loss of or inability to obtain adequate protection for intellectual property rights; litigation; loss of key executives or other employees; and adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer 4 2014 performance Outlook 5 2014: Targets achieved Targets for 2014 Group sales Low to mid-single digit growth1 FY 2014 +5% +5% Core EPS Ahead of sales growth1 +7% excl. one-time US Pharma fee2 Dividend Further increase dividend3 CHF 8.00 +3% At constant exchange rates One-time double charge of CHF 202m for the US Branded Prescription Drug fee in 2014, following final regulations issued by the US Internal Revenue Service which advanced the timing of recording the liability 3 2014 dividend as proposed by the Board of Directors 1 2 6 2014: Highlights Growth • Group sales +5%1 driven by HER2 franchise (+20%1), Avastin (+6%1), Actemra (+23%1) and Professional Diagnostics (+8%1) • Outperformance in all major regions: +6%1 in US, Japan & International; +3%1 in Europe Innovation • Three Breakthrough Therapy Designations: Anti-PDL1, Esbriet and Lucentis • Three Fast Track Designations: Lampalizumab, cobimetinib and LptD (antibiotic) • Cancer immunotherapy: New PD-L1 data in bladder, TNBC, renal. Six new agents entered clinic • Phase 3 starts: Lampalizumab, etrolizumab, alectinib, venetoclax and Kadcyla adjuvant • Launched next generation molecular diagnostics platform (cobas 6800/8800) M&A • InterMune: Acquisition completed • Foundation Medicine: Collaboration announced 1 CER=Constant Exchange Rates 7 First take on Swiss National Bank`s decision On January 15, the Swiss National Bank (SNB) announced its decision to unpeg the Swiss franc from the Euro Natural hedge of the underlying business: • 18% of operating costs in Switzerland • US, Europe, Japan and China with complete value chain • Interest expenses predominantly paid in USD • 2015 dividend payout for March converted prior to SNB decision 8 2014: Solid sales growth 2014 2013 CHFbn CHFbn CHF CER Pharmaceuticals Division 36.7 36.3 1 4 Diagnostics Division 10.8 10.5 3 6 Roche Group 47.5 46.8 1 5 CER=Constant Exchange Rates Change in % 9 2014: Continued sales growth for 4 years 10% 8% 8% 7% 6% 6% 6% 5% 5% 4% 4% 4% 2% 0% 6% 6% 4% 4% 2% 0% 0% Q1 11 Q2 11 1% Q3 11 Q4 11 Q1 12 All growth rates at Constant Exchange Rates (CER) Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 10 2014: Both Divisions with sales growth in all regions CHFbn 20 +6% 18 +4% 16 +3% 14 +6% 12 +2% Diagnostics +13% 10 +6% 8 6 +6% 4 0% 2 +7% +2% Pharma +3% 0 Japan International All growth rates at Constant Exchange Rates (CER) Europe US 11 2014: Group core operating profit & margin remains at high levels 34,9% 35,6% 37,7% 38,3% 37,2% (37.6%*) +3% at CER (+5%*) CHFbn 16,6 2010 17,2 17,9 17,6 2013 2014 % of sales 15,1 2011 2012 CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in 2014 12 2014: Core EPS growth bridge +1.7% +5.2% +6.9% one-time US Pharma fee* +4.9% Sales Core EPS Full Year 2014 figures as reported CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in 2014 Core EPS Full Year 2014 excl. one-time US Pharma fee* 13 2014: Dividend and payout ratio further increased CHF Dividend payout ratio (%) 10,00 55,3 9,00 8,00 51,6 48,6 44,8 2014 payout ratio: 56.0% 7,00 6,00 5,00 31,9 54,7 54,5 56.0 8.00 38,8 34,5 4,00 3,00 2,00 1,00 0,00 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 Payout ratio calculated as dividend per share divided by core earnings per share (diluted); 2014 dividend as proposed by the Board of 1 compound annual growth rate Directors; Note: For 1995, a special dividend was paid out to mark F. Hoffmann-La Roche’s 100th anniversary in 1996 2014 14 Roche: A pipeline of differentiated products Oncology Launched Phase III Phase II Avastin Rituxan/MabThera Herceptin Xeloda Tarceva Zelboraf Erivedge Perjeta Kadcyla Gazyva/Gazyvaro Oncology Immunology/ Ophthalmology Esbriet Pulmozyme Neuroscience Ophthalmology Immunology Xolair Actemra/RoActemra Rituxan/MabThera RA Lucentis pictilisib1 taselisib1 anti-PDL1 venetoclax (Bcl2i) cobimetinib4 alectinib lampalizumab3 ocrelizumab gantenerumab 10 NMEs + 9 AIs 3 AIs 6 NMEs lebrikizumab etrolizumab2 Neuroscience Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma AI = Additional Indication; NME = New Molecular Entity 1 15 2014 performance Outlook 16 2015 milestones Launch new products Expand cancer immunotherapy Renew CD20 franchise Esbriet: US and EU Cobimetinib + Zelboraf: US and EU PD-L1: Bladder, Lung, Renal, Triple Negative BC NMEs: OX40, CD40, CEA-IL2, CSF1R, IDO, CEA-CD3 Gazyva (aggressive NHL)* Entry into Hemophilia ACE910: Start of pivotal trials Entry into Multiple Sclerosis Ocrelizumab: Phase 3 readout Diagnostics * Event-driven (interim analysis) Rollout of key platforms (cobas 6800 / 8800) 17 2015 outlook 1 At 2 Group sales growth1 Low to mid-single digit Core EPS growth1 Ahead of sales growth2 Dividend outlook Further increase dividend in Swiss francs constant exchange rates Excluding sale of filgrastim rights in 2014 18 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals 19 2014 results Innovation Outlook 20 2014: Pharma sales All regions with positive growth 2014 2013 CHFm CHFm 36,696 36,304 1 4 15,822 15,097 5 6 Europe 9,422 9,254 2 3 Japan 3,301 3,405 -3 7 International 8,151 8,548 -5 2 Pharmaceuticals Division United States CER=Constant Exchange Rates Change in % CHF CER 21 2014: Pharma Division Investment in Esbriet launch 2014 CHFm % sales Sales Royalties & other op. inc. Cost of sales M&D R&D G&A Core operating profit 36,696 100.0 2,273 -7,551 -5,974 -7,876 -1,567 6.2 -20.5 -16.3 -21.5 -4.3 16,001 43.6 2014 vs. 2013 CER growth Excl. 340B: +5% 4% Excl. filgrastim deal: +10% 35% 4% Esbriet launch 6% 4% PSI Excl.&PSI & US US Pharma fee* Pharma fee*:+14% 50% 4% -1% in CHF CER=Constant Exchange Rates * Refers to 2013 past service income of CHF 131m and one-time double charge for the US Branded Prescription Drug fee in 2014 22 2014: Pharma sales HER2, Avastin and Tamiflu main growth drivers Perjeta +189% Herceptin +7% Avastin +6% Tamiflu +54% Kadcyla +135% Actemra/RoActemra +23% Xolair +25% MabThera/Rituxan Pegasys +2% US Europe Japan International -20% Xeloda -46% CHFm -800 -400 Absolute amounts and growth rates at Constant Exchange Rates (CER) 0 400 800 23 2014: Oncology sales up +5% CER growth Perjeta HER2 +20% +20% Herceptin • Strong uptake of Perjeta & Kadcyla Kadcyla MabThera/ Rituxan • Continued uptake in ovarian & cervical (US) • Treatment through multiple lines in CRC +6% +6% Avastin Tarceva -1% -1% Xeloda -46% -46% • In-class competition • Loss of exclusivity • Competitive pressure in US & EU • Potential approval of coBRIM in 2015 -12% -12% Zelboraf CHFbn • Increased usage across a variety of indications • Growth despite 340B baseline effect and Russia +2% +2% 0 3 CER=Constant Exchange Rates 6 9 2014 Oncology sales: CHF 22.8bn 24 Avastin: Growth supported by recent launches CHFm YoY CER growth 7,000 6,000 +6% +13% +6% Platinum-resistant ovarian cancer • Launched in US and EU -7% Cervical cancer 5,000 • Launched in US and filed in EU 4,000 HER2 negative breast cancer 3,000 2,000 • Positive phase 3 data in treatment through multiple lines (TML) and 1L 1,000 Colorectal cancer 0 2011 US 2012 Europe CER=Constant Exchange Rates 2013 International 2014 • CALGB H2H data support standard of care in 1L Japan 25 HER2 franchise: Strong growth driven by Perjeta and Kadcyla CHFm YoY CER growth 2.500 2.000 1.500 16% 15% 7% 15% 20% 17% 23% 23% 19% 10% Kadcyla Perjeta 1.000 Herceptin 500 0 Q3 12 Q4 12 CER=Constant Exchange Rates Q1 13 Q2 13 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 26 Immunology products: Accelerated growth Driven by Actemra SC and Xolair CHFm 800 600 26% 19% 18% 18% 20% 19% YoY CER growth 18% 15% Actemra SC Actemra IV 400 Xolair Pulmozyme 200 0 Q1 13 Q2 13 CER=Constant Exchange Rates Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 27 Lucentis: Flattening in a competitive environment Breakthrough designation in Diabetic Retinopathy Lucentis sales (USDm) 500 2014 • Growth driven by DME and continued market expansion 400 300 Eylea wAMD AMD Less-frequent than monthly dosing Lucentis DME Outlook • Increased competition in AMD and DME • Breakthrough Status and Priority Review for treatment of DR (PDUFA date Feb 6) 200 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 11 11 12 12 12 12 13 13 13 13 14 14 14 14 AMD=wet age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy 28 Esbriet strong launch Esbriet sales CHFm 50 50 45 40 40 33 30 30 • FDA approval on 15 October 2014, patients still in transition to full reimbursement 28 24 • > 1,300 patients in clinical trials 18 20 20 10 10 37 10 13 European sales with strong growth 00 Q1 13 13 Q2 13 13 US launch off to strong start Q3 13 13 Europe Europe Q4 13 13 Q3 Q1 14 13 14 Canada Canada Sales based on average 2013 exchange rate Q2 14 14 Q3 14 14 Q4 14 • EU label strengthened to include the ASCEND and pooled one year mortality data on October 23, 2014 US US 29 2014 results Innovation Outlook 30 2014: Major clinical and regulatory news flow Regulatory Phase III Phase III starts Compound Indication Milestone Actemra SC Rheumatoid arthritis EU approval Avastin Glioblastoma EU approval Avastin Cervical cancer Avastin Pt-resistant ovarian cancer MabThera SC NHL Gazyvaro Front line CLL Xolair Chronic idiopathic urticaria Esbriet Idiopathic pulmonary fibrosis oral octreotide Acromegaly cobimetinib BRAF+ met. melanoma gantenerumab Prodromal Alzheimer`s disease Kadcyla/Perjeta 1L met. HER2+ breast cancer Esbriet Idiopathic pulmonary fibrosis Kadcyla Adjuvant HER2+ breast cancer Kadcyla Neo-adjuvant HER2+ breast cancer venetoclax (Bcl2 inh.) Relapsed/refractory CLL Anti-PDL1 2/3L NSCLC alectinib ALK+ NSCLC etrolizumab Ulcerative colitis gantenerumab Mild Alzheimer`s disease lampalizumab Geographic atrophy US, EU filing US, EU approval EU approval EU approval US approval US approval Ph III Ph III (co-BRIM) Ph III (SCarlet RoAD) Ph III (MARIANNE) Ph III (ASCEND) Ph III (KAITLIN) Ph III (KRISTINE) Ph III (MURANO) Ph III (OAK) Ph III (ALEX) Ph III (HIBISCUSI/II, GARDENIA, LAUREL, HICKORY, COTTONWOOD) Ph III (Marguerite RoAD) Ph III (CHROMA, SPECTRI) 31 Roche: A pipeline of differentiated products Oncology Launched Phase III Phase II Avastin Rituxan/MabThera Herceptin Xeloda Tarceva Zelboraf Erivedge Perjeta Kadcyla Gazyva/Gazyvaro Oncology Immunology/ Ophthalmology Esbriet Pulmozyme Neuroscience Ophthalmology Immunology Xolair Actemra/RoActemra Rituxan/MabThera RA Lucentis pictilisib1 taselisib1 anti-PDL1 venetoclax (Bcl2i) cobimetinib4 alectinib lampalizumab3 ocrelizumab gantenerumab 10 NMEs + 9 AIs 3 AIs 6 NMEs lebrikizumab etrolizumab2 Neuroscience Phase III decision pending; 2 FPI in 1H 2014; 3 FPI in 2H 2014; 4 Filed in combination with Zelboraf in metastatic melanoma AI = Additional Indication; NME = New Molecular Entity 1 32 HER2 franchise expected to grow further Biosimilars delayed to 2017 Est. Biosimilars launch (EU) 2nd line mBC Xeloda + lapatinib 1st line mBC Herceptin + chemo Adjuvant BC Herceptin + chemo Kadcyla (EMILIA) Herceptin & Perjeta + chemo (CLEOPATRA) Herceptin sc + chemo (HannaH) Neoadjuvant Herceptin + chemo BC (NOAH)1 2011 2012 Established standard of care Herceptin & Perjeta + chemo (APHINITY) Herceptin & Perjeta + chemo (Neosphere, Tryphaena)2 2013 2014 2015 Kadcyla & Perjeta + chemo (KRISTINE) 2016 2017 New standard of care 2018 Kadcyla (KATHERINE) Kadcyla & Perjeta (KAITLIN) 2019 2020 Potential new standard of care Key priorities in 2015 • Strengthen PERJETA as standard of care in 1L mBC & neoadjuvant, Kadcyla in 2L • Secure durable conversion from Herceptin IV to SC Clinical data in 2015 • PERJETA 2L PHEREXA final PFS & interim OS data expected Q3 15 • Release of the NEOSPHERE final PFS/DFS data at ASCO 33 Hematology franchise Extensive late stage clinical trial program Biosimilars delayed to 2017 * Partnered with AbbVie venetoclax (Bcl2 inhibitor); polatuzumab vedotin (CD79b ADC) Compound Combination Indication P1 P2 Gazyva Mono GREEN R/R CLL Gazyva Mono GOYA aNHL Gazyva Mono GADOLIN iNHL Gazyva Mono GALLIUM 1L FL Gazyva +PDL1 R/R FL Gazyva +PDL1 aNHL venetoclax* +Rituxan MURANO R/R CLL venetoclax +Gazyva CLL14 CLL venetoclax Mono R/R CLL 17p venetoclax +Rituxan R/R FL venetoclax Mono 1L aNHL venetoclax Mono R/R NHL venetoclax Mono R/R MM venetoclax Mono AML polatuzumab +Rituxan/Gazyva NHL polatuzumab +Gazyva R/R FL polatuzumab +Gazyva aNHL P3 34 Anti-PDL1 in triple negative breast cancer Encouraging early data TNBC a PD-L1 IHC (IC) n ORR, Best Response, b % (95% CI) PD-L1+ vs PD-L1- ORR, b % (95% CI) IHC 3 6 17% (1,60) IHC 2 3 67% (14,98) IHC 1 - - - IHC 0 - - - 33% (10,70) • Encouraging efficacy in monotherapy • Well tolerated • Update at a medical conference in 2015 Emens LA, et al. SABCS, 2014 35 2014 Roche cancer immunotherapy: Six NMEs moved into the clinic T cell Trafficking New in 2014 Priming & activation Anti-CEA-IL2v Anti-OX40 NME (Anti-ctyokine) T cell infiltration Anti-CD27* Anti VEGF: Avastin Antigen presentation Anti-CD40 IMA942 vaccine* Cancer T cell recognition (Immatics) Anti-CEA-CD3 Anti-HER2-TDB Antigen/T cell bispecific Mabs ImmTAC* (Immunocore) T cell killing Clinical development Preclinical development Established therapies * Partnered projects (external) Chen and Mellman. Immunity 2013 Antigen release Targeted therapies: Tarceva, cobimetinib, Zelboraf, Gazyva Anti-PD-L1 Anti-CSF-1R Anti-CEA-IL2v Anti-OX40 IDO inhibitor (NewLink Genetics) NME (undisclosed) IDO inhibitor* (Incyte) 36 Cancer immunotherapy program growing strongly Compound Combination Indication PDL1 Mono +Tarceva Lung PDL1 Mono Bladder PDL1 PDL1 Mono +Avastin +Zelboraf +Zelboraf+cobimetinib Renal Melanoma Mono +Avastin +cobimetinib +ipilimumab +IFN alfa-2b +CD40 +OX40 +CSF-R1 +CEA IL2v Solid tumors PDL1 +Avastin+FOLFOX Colorectal PDL1 Mono +Gazyva Hematology PDL1 Mono PDL1 Triple negative breast cancer CSF-1R Mono +CD40 Solid tumors CEA IL-2v Mono Solid tumors OX40 Mono Solid tumors Mono Mono Solid tumors CEA CD3 IDO Study ongoing Solid tumors Study imminent Additions since Q3 Ph 1 Ph 2 Ph 3 Status as at January 2015 37 Roche cancer immunotherapy Pipeline as of 2014 year end… Phase I Anti-PDL1+Tarceva NSCLC Anti-PDL1+Zelboraf Melanoma Anti-PDL1 Solid tumors Anti-PDL1+Avastin Solid tumors Anti-PDL1+cobimetinib Solid tumors Anti-PDL1+ipilimumab Solid tumors Anti-PDL1+IFN-alfa Solid tumors Anti-PDL1+ CD40 Solid tumors PDL1+Avastin+FOLFOX CRC Anti-PDL1 + Gazyva Blood cancer Anti-PDL1 TNBC Anti-CSF1R Solid tumors Anti-CEA IL-2v Solid tumors Status as at December 2014 Phase II Anti-PDL1 NSCLC (Dx+) Anti-PDL1 NSCLC 2/3L Anti-PDL1+Avastin Renal 1L Anti-PDL1 Bladder 1/2L Anti-OX40 Solid tumors CEA CD3 Solid tumors IDO Solid tumors Phase III Anti-PDL1 NSCLC 2/3 L Anti-PDL1 trials NMEs monotherapy Immune doublets 38 Roche cancer immunotherapy …and additional trials already decided upon Phase I Anti-PDL1+Tarceva NSCLC Anti-PDL1+Zelboraf Melanoma Anti-PDL1 Solid tumors Anti-PDL1+Avastin Solid tumors Anti-PDL1+cobimetinib Solid tumors Anti-PDL1+ipilimumab Solid tumors Anti-PDL1+IFN-alfa Solid tumors Anti-PDL1+ CD40 Solid tumors PDL1+Avastin+FOLFOX CRC Anti-PDL1 + Gazyva Blood cancer Anti-PDL1 TNBC Anti-CSF1R Solid tumors Anti-CEA IL-2v Solid tumors Status as at January 28, 2015 Phase II Anti-OX40 Solid tumors CEA CD3 Solid tumors IDO Solid tumors Anti-PDL1 + OX40** Solid tumors Anti-PDL1 + CSF1R** Solid tumors Anti-PDL1 + CEA-IL2v** Solid tumors Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1 NSCLC (Dx+) Anti-PDL1 NSCLC 2/3L Anti-PDL1+Avastin Renal 1L Anti-PDL1 Bladder 1/2L Anti-PDL1 trials NMEs monotherapy Phase III Anti-PDL1 NSCLC 2/3 L Anti-PDL1** Bladder 2L Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Anti-PDL1** tba Immune doublets 2015 readout expected ** Study start in 2015 39 Oncology – Molecular Information How we will collaborate with Foundation Medicine Roche/FMI R&D Collaboration 1. Comprehensive tumor analysis in Roche Clinical Trials DNA & RNA sequencing 2. We will innovate together Immunotherapy Panel Blood based continuous monitoring What we aim to achieve together Key initial areas for collaboration • Cancer Immunotherapy test • Continuous monitoring test Brings together expertise needed to innovate for patients • Roche a leader in PHC/companion diagnostics across modalities • FMI a leader in comprehensive genomic profile development and molecular information 40 ACE 910 in Hemophilia A FVIIIa NON-INHIBITOR A novel FVIIIa mimetic bispecific antibody INHIBITOR ACE 910 Kitazawa, Shima, Yoshioka, Hattori . Nature Medicine 2012;18(10):1570, Sampei, et al. PLoS One 2013;8(2):e57479, Muto, Shima, Hattori . J Thromb Haemost 2014;12:206 On-demand treatment 1-3 times/bleeding event, IV Prophylaxis 3 times/week, IV Inhibiting Factor VIII antibodies in 20-33% of the patients Immune Tolerance Induction 70-80 % success rate limitation due to very high cost and heavy burden for patients On-demand treatment with bypassing agents 2-3h intervals, IV Prophylaxis with bypassing agents Every other day, IV Mode of action Targeted product profile Novel approach promoting FX activation and acceleration of coagulation • Less frequent dosing • Subcutaneous • Avoid induction of inhibiting antibodies In collaboration with Chugai 41 2014 results Innovation Outlook 42 2015: Key late-stage news flow Regulatory Phase III readouts* Phase III starts Phase II readouts* Compound Indication Milestone Avastin Cervical cancer EU approval Lucentis Diabetic retinopathy US approval alectinib ALK+ NSCLC US filing Cobimetinib + Zelboraf 1L Melanoma US, EU approval Gazyva Front line aNHL Ph III GOYA (interim) ocrelizumab Relapsing MS (RMS) Ph III OPERA I/II ocrelizumab Primary progressive MS (PPMS) Ph III ORATORIO Perjeta 2L HER2+ mBC Ph III PHEREXA Kadcyla HER2+ gastric cancer Ph II/III GATSBY Anti-PDL1 Bladder Ph III Anti-PDL1 Tumor type 1 Ph III Anti-PDL1 Tumor type 2 Ph III Anti-PDL1 Tumor type 3 Ph III Etrolizumab Crohn`s disease Ph III ACE910 Hemophilia A Ph III taselisib (PI3K inhib) HR+/PI3Kmut BC Ph III SANDPIPER Anti-PDL1 2/3L NSCLC Ph II FIR, POPLAR, BIRCH Anti-PDL1 Bladder Ph II ipatasertib (AKT inhib) Gastric/prostate cancers Ph II A.MARTIN, JAGUAR * Outcome studies are event driven, timelines may change 43 Diagnostics Division Roland Diggelmann COO Roche Diagnostics Picture 44 2014: Diagnostics Division sales Growth driven by Professional Diagnostics 2014 2013 CHFm CHFm 10,766 10,476 3 6 Professional Diagnostics 6,045 5,772 5 8 Diabetes Care 2,392 2,459 -3 1 Molecular Diagnostics 1,613 1,580 2 6 716 665 8 10 Diagnostics Division Tissue Diagnostics Underlying growth of Molecular Diagnostics excluding Sequencing Solutions: +8% CER=Constant Exchange Rates Change in % CHF CER 45 2014: Diagnostics regional sales Growth driven by APAC and EMEA Japan North America 0% +4% EMEA1 25% of divisional sales +4% 4% of divisional sales 45% of divisional sales Latin America +13% 7% of divisional sales Asia Pacific +15% 19% of divisional sales 16% growth in E7 countries2 1Europe, Middle East and Africa; 2Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at constant exchange rates 46 2014: Diagnostics Division Profit growth in line with sales excl. PSI* 2014 CHFm % sales Sales Royalties & other op. inc. Cost of sales M&D R&D G&A Core operating profit 2014 vs. 2013 CER growth 10,766 100.0 6% 131 -4,790 -2,462 -1,037 -512 1.2 -44.4 -22.9 -9.6 -4.8 2% 2,096 19.5 Excl. VAT*: +8% 9% Excl. VAT*: +8% 4% 3% Admin: +6% Excl. PSI*: +5% Excl. PSI*: +5% and VAT*: +8% 21% 2% -4% in CHF CER=Constant Exchange Rates * PSI: 2013 past service income of CHF 67m; VAT: 2013 one-time VAT refund of CHF 45m 47 2014: Diagnostics Growth driven by Professional Diagnostics CER growth Professional Dia +8% • Continued double digit growth in immunodiagnostics (+13%) • Further expansion of leading menu Diabetes Care +1% Molecular Dia 1 1 Underlying • Virology (+7%) incl. HPV (+48%) • Launch of cobas 6800/8800 systems with assays for blood screening and virology +6% Tissue Dia Sales CHFbn • Accu-Chek Aviva/Performa (+7%) and Mobile (+19%) +10% 0 1 2 • Advanced staining portfolio (+9%) and companion diagnostics (+27%) EMEA North America RoW 3 4 5 6 growth of Molecular Diagnostics excluding Sequencing Solutions: +8% CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 48 Serum work area (42% of sales)* Growing strongly in all regions +10% Integrated SWA* solution +8% +15% – Immunodiagnostics (+13%) – Clinical chemistry (+7%) *SWA: serum work area: clinical chemistry and immunodiagnostics Latin America +8% North America +19% Asia-Pacific +5% 2013 Japan EMEA 2014 49 Invest for growth New reagent manufacturing in China RPD reagent volume • Reliable local supply and right sizing of cost base Asia Other x2 • Reagent formulation, filling and packaging – Packaging to begin in 2016 – Fully operational in 2018 2012 2017E RPD = Roche Professional Diagnostics 2022E 50 Extend leading menu in women’s health High prognostic value of preeclampsia blood test Assay and claim extension • Extends the applicability of the assay from 3-5% of pregnancies to 20% • Fully automated • Test performed across entire cobas analyzer platform series * Hund, M., et al. (2014) BMC Pregnancy and Childbirth 14, 324; Zeisler, H.,. et al. (2014) XX COGI World Congress 2014 *Preeclampsia can be ruled-out for 1 week after testing 51 Molecular Diagnostics Launch and implementation of cobas 6800/8800 High Throughput Reference Labs cobas® 8800 • Advanced PCR automation • Highest throughput (3x above closest competitor) • CE launch of blood screening and virology assays Large Hospitals cobas® 6800 • Low to middle volume throughput • Broadest menu incl HPV testing Medium Hospitals cobas® 4800 Low Throughput 52 Entering Molecular Point of Care Diagnostics Acquisition of IQuum, launch of cobas Liat™ analyzer Liat™ Analyzer Liat™ tube Target market: • ~CHF 350m, growing ~20% p.a. Laboratory in a tube technology: • Fast and easy to use • CLIA waiver expected in 2015 Portfolio: • Influenza A/B and Strep A test, CE marked and FDA cleared • Plans to extend menu in: – Respiratory Syncytial Virus tests – MRSA and C-difficile Point of Care: e.g. physician’s office, emergency rooms, ambulance, pharmacies; MRSA: methicillin resistant Staphilococcus aureus 53 Sequencing strategy Building a leading sequencing solution Developing complete sequencing solutions Grow through disruptive innovation Sample preparation Testing platform Menu of assays Data analysis Abvitro: Technology acquisition; Ariosa: Acquisition; Genia: Acquisition; Pacific Biosciences: Partnership; Bina: Acquisition; Foundation Medicine: Partnership Reporting 54 Sequencing menu: Non-invasive prenatal testing Acquisition of Ariosa HarmonyTM Prenatal Test Target market • USD 400m sales worldwide in 2013, +30% pa Technology • Analyses fetal DNA with microarray technology • Highly cost effective and accurate • Screens for the risk of Down, Edwards and Patau syndrome Digital analysis of selected regions (DANSRTM) technology Strategy • Expand market access through kit distribution model • Add test to Roche sequencing platform when available 55 Key launches 2014 Instruments / Devices Tests / Assays Area Product Labs cobas 6800/8800 – Next generation molecular (PCR) system cobas m 511 – Fully integrated and automated hematology system cobas 6500 – Automated urinalysis work area platform Connect-V – Middleware providing connectivity to LIS2 Diabetes Care Infectious Diseases / Blood Screening Microbiology Women’s Health *Excluding Accu-Chek Insight- Next generation insulin pump & bGm3 system Accu-Chek Connect – bG meter with connectivity to smart phones, mobile App and cloud MPX 2.0 – Next generation blood screening multiplex test MPX (HIV, HCV, HBV), HEV, DPX4, WNV5 – Full NAT blood screening menu for cobas 6800/8800 HIV, HCV, HBV – Virology tests for cobas 6800/8800 HSV- Detection of Herpes Simplex Virus on cobas 4800 Syphilis– Immunoassay for the detection of Treponema pallidum MRSA/SA – Next generation assay on cobas 4800 C-difficile – Diagnosis of infections and associated diarrhea PE Prognosis- Claim extension for short-term prediction of Preeclampsia in pregnancy AMH- Assessment of ovarion reserve for fertility Market WW* EU EU WW RMD RPD RPD RTD EU RDC EU RDC US RMD WW* RMD WW* RMD EU RMD EU RPD EU EU RMD RMD EU EU RPD RPD US; Areas: RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics, RTD: Roche Tissue Diagnostics; 2 hospital information systems; 3 blood glucose monitoring; 4 parvovirus B19 and hepatitis A virus; 5 west nile virus 1 Business BA1 56 Key launches 2015 Area Laboratory Instruments / Devices Tests / Assays Diabetes Care Product Market BA1 cobas c 513 – dedicated HbA1C analyzer RPD EU cobas t 411– core lab coagulation analyzer EU RPD WW cobas 8100 V2 – Integrated pre- and post-analytical solution RPD ® US cobas 6800/8800 – Medium to High volume automated real-time PCR RMD WW RTD VENTANA HE 600 – automated H&E staining platform Accu-Chek Active no-code– next-gen. bG meter, no coding of test strips WW RDC Accu-Chek Connect – bG meter with connectivity to smartphones, mobile US RDC applications and cloud Point of Care CoaguChek® Pro II - professional system for PT and aPTT testing EU RPD Blood Screening cobas® 6800/8800 MPX – Multiplex Bloodscreening test US RMD Infectious Diseases cobas® Liat Influenza A/B + RSV – POC detection HTLV– human T-lymphotropic virus diagnostics test cobas® 6800/8800 HBV – Quantitative HBV viral load test cobas® 4800 HIV-1 - Quantitative HIV viral load test cobas® 4800 HCV – Quantitative HCV viral load test cobas® 4800 HBV – Quantitative HBV viral load test US EU RMD RPD EU EU EU EU RMD RMD RMD RMD EU RMD EU RPD Virology Genomics & cobas® EGFR Test v2 - detection of EGFR in plasma Oncology Cardiac Cobas h 232 Troponin T – Point of Care test version of Elecsys cTNT-hs Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics; RTD: Roche Tissue Diagnostics; 1 57 Outlook Investing into future growth • Continued strong growth in serum work area • Focus on implementation of next generation platforms, e.g. cobas 6800/8800 • Continued investment into development of future sequencing solution • Ongoing structural adjustments in Diabetes Care to adapt to continuing challenging market environment • Strengthen leading presence in emerging markets 58 Finance Alan Hippe Chief Financial Officer 59 2014: Highlights Business • Solid sales and Core EPS growth: +5%1; Core EPS +7%1 excluding US Pharma fee* • Core operating profit up +3%1 or +5%1 excluding US Pharma fee* • Cash generation remains strong with operating FCF of CHF 15.8bn, a decrease of -2%1 due to higher capital investments • Accounts receivable in Southern Europe further decreased Improved financial result and major currency impact • Positive development of Core Net Financial result: +32%1 due to sale of equities and lower interest expenses • Increased net debt due to acquisitions • Group currency exposure – solid natural hedge, 82% of cost base outside Switzerland CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in 2014 1 60 2014: Group currency exposure Overall solid natural hedge Currency exposure 50% Sales Operating costs 40% 41% 38% 30% 28% 20% 21% 21% 18% 17% 10% 8% 0% 6% 2% CHF USD EUR JPY FY 2014 currency structures; operating costs include all items between the sales and the operating profit lines Others 61 2014 performance Focus on cash 62 2014: Group performance Core EPS growth +5%1 or +7%1 excl. US Pharma fee* Sales Core operating profit as % of sales Core net income as % of sales Attributable to Roche shareholders Core EPS (CHF) Operating free cash flow as % of sales Free cash flow as % of sales 2014 2013 CHFm CHFm 47,462 17,636 37.2 12,533 26.4 12,329 46,780 17,904 38.3 12,526 26.8 12,316 1 -1 5 3 5 0 6 7 0 6 7 14.29 14.27 0 5 7 15,778 33.2 5,322 11.2 16,381 35.0 5,403 11.5 -4 -2 -1 1 CER=Constant Exchange Rates * Excluding one-time double charge for the US Branded Prescription Drug fee in 2014 1 Change in % CHF Excl. US CER Pharma fee* 63 2014: Group operating performance Core OP growth +3%1 or +5%1 excl. US Pharma fee* 2014 CHFm % sales Sales Royalties & other op. inc. Cost of sales M&D R&D G&A Core operating profit 2014 vs. 2013 CER growth 47,462 100.0 2,404 -12,341 -8,436 -8,913 -2,540 5.1 -25.9 -17.8 -18.8 -5.4 Excl. filgrastim deal: +10% 17,636 37.2 Excl. US Pharma fee*: +5% 5% 33% 6% 6% 4% Excl. PSI and US Pharma fee*:+8% 38% 3% -1% in CHF CER=Constant Exchange Rates * US Pharma fee: one-time double charge for the US Branded Prescription Drug fee in 2014; PSI: 2013 past service income of CHF 302m 1 64 2014: Core operating profit and margin Margin at high levels 44.0% 37.7% 38.3% CHFm 37.2% (-0.1%p2) -0.5 %p1 (-1.1 %p) 1 +3 % (-1 %) 17,160 17,904 17,636 44.4% 43.6% (+0.3%p2) -0.2 %p1 (-0.8 %p) +4 %1 (-1 %) 15,488 16,108 16,001 % of sales 21.3% 20.8% 19.5% -0.9 %p1 (-1.3 %p) +2 %1 (-4 %) 2012 2013 Roche Group 1 CER=Constant 2 At 2,187 2,177 2,096 2014 Pharma Division Exchange Rates CER excluding one-time double charge for the US Branded Prescription Drug fee in 2014 Diagnostics Division 65 2014: Core net financial result Higher income from equities and lower interest expenses CHFm 0 -500 -1.116 -1.699 Improvement of 34% in CHF / 32% at CER -1.000 +136 +69 Interest expense FX gains/losses +90 +288 -1.500 -2.000 2013 CER=Constant Exchange Rates Net income from equity securities All other, net 2014 66 Balance sheet 31 December 2014 Equity ratio at 29% due to acquisitions CHFbn CHFbn 75.6 Cash and marketable securities 11.7 62.2 11.9 19% Other current assets Non-current assets Current liabilities 62.2 23.1 19.4 15.8 31% 26% 25% 15% 17.3 28% 33.0 44.5 53% 59% 31/12/13 31/12/14 Assets CER=Constant Exchange Rates 75.6 Non-current liabilities 25.2 Equity (Net assets) 41% 30.9 Net debt/ 40% total assets: 19% 21.2 21.6 34% 29% 31/12/13 31/12/14 Equity & liabilities 67 2014: Group core tax rate Double R&D tax credits in 2013 Figures in % +1.0 +0.4 Relative higher core profits in US US R&D tax credits for 2012 and 2013, included in 2013 while only one year credits in 2014 22,7 2013 Profit mix US 24,1 2014 68 2014 performance Focus on cash 69 2014: Operating free cash flow remains at high levels 41.8% 35.5% 35.0% 33.2% -2.4 %p1 (-1.8 %p) -2 %1 (-4 %) CHFm 16,135 16,381 15,778 41.3% 40.4% % of sales -1.7 %p1 (-0.9 %p) 0 %1 (-1 %) 18.4% 18.7% 13.2% 14,710 14,976 14,821 -5.3 %p1 (-5.5 %p) -24 %1 (-28 %) 2012 2013 Roche Group CER=Constant Exchange Rates 1,890 1,962 2014 Pharma Division 1,417 Diagnostics Division 70 2014: Accounts receivable in Southern Europe further decreased B BB Dec 2014 161 185 251 236 Greece Dec 2013 Dec 2012 97 114 163 209 Portugal Dec 2011 433 BBB- 733 819 Italy 980 480 BBB 613 604 Spain 1.036 Southern European Countries 1.171 0 1 CER=Constant 400 800 1.200 Exchange Rates Note: Sovereign country ratings from Standard & Poor’s, as of 7 January 2015 1.645 1.836 1.600 2.000 -52%1 2.462 2.400 2.800 CHFm 71 2014: Group net debt development Higher net debt due to InterMune acquisition Free Cash Flow CHF 5.3bn 1% (CER) higher than 2013 CHFbn +15.8 -10.5 -6.7 -14,0 -12.6 Dividends Taxes Treasury Net debt 31 Dec 2013 CER=Constant Exchange Rates Operating Free Cash Flow Non-op. FCF -6.7 -3.0 -0.8 Business comb. Own equities Other -9.6 -0.8 -2.2 Business combinations, Net debt Currency translation 31 Dec 2014 & other 72 Balance sheet: Net debt to total assets Ratio higher than 2013 due to InterMune acquisition 19% Net debt / total assets 16% 11% 75.6 Total assets (CHFbn) Net debt (CHFbn) 14.0 31 Dec 2012 31 Dec 2013 31 Dec 2014 73 December 2014: Debt maturity profile Balanced maturity profile CHFbn 5 GBP CHF EUR USD 4 3 2 1 0 2015 2016 2017 2018 2019 2021 2022 2023 2024 2035 2039 2044 Of the CHF 48 bn bonds and notes issued to finance the Genentech transaction, cumulative CHF 36 bn have been repaid as of December 31, 2014* Nominal values @ actual FX rates; *Original net proceeds in CHF 74 Currency impact on Swiss franc results 2014 Negative currency impact CHF / USD Assumed average YTD 2014 Average YTD 2013 0.93 -4% 0.89 +1% 0.90 0.89 0.88 0.88 0.89 0.94 0.93 -5% -4% +1% 0.89 0.90 0.90 0.90 0.91 Monthly avg fx rates 2014 J F M A 0.94 0.93 -1% In 2014 impact is (%p): 0.91 0.95 0.96 0.98 Fx rates at 31 Dec 2014 M J J A S O N D Sales CHF / EUR 1.23 1.22 1.23 1.23 1.23 1.22 -1% -1% 1.22 1.21 -1% +2% 0% +2% 1.23 1.22 1.22 1.22 1.22 1.22 1.22 1.21 1.21 1.21 1.20 1.20 J F M A M J J A S O N D Q1 HY Sep YTD FY -6 -6 -5 -4 Core operating profit -8 -4 Core EPS -8 -5 75 Currency sensitivities for 2014 Impact of 1% change in average exchange rate vs. the Swiss franc Sales Core OP 190 76 Euro 98 48 Japanese yen 37 20 131 70 Figures in CHFm US dollar All other currencies 76 2015 outlook 1 At 2 Group sales growth1 Low to mid-single digit Core EPS growth1 Ahead of sales growth2 Dividend outlook Further increase dividend in Swiss francs constant exchange rates Excluding sale of filgrastim rights in 2014 77 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 sales Diagnostics Foreign exchange rate information 78 Changes to the development pipeline FY 2014 update New to Phase I New to Phase II New to Phase III New to Registration 11 NMEs RG6047 SERD (2) – ER-pos (HER2neg) mBC RG6078 IDO inh - solid tumors RG7802 CEA CD3 TCB - solid tumors RG7876 CD40 iMAb+PD-L1 MAb solid tumors RG7787 MSLN-PE cFP – solid tumors RG7689 NME – infectious diseases RG7880 NME - autoimmune diseases RG7625 NME - autoimmune diseases RG6080 DBO β-lactamase inh bacterial infections RG7345 TAU pS422 MAb – AD RG7597 HER3/EGFR DAF+cobimetinib – KRAS mutation-pos tumors 2AIs RG7155 CSF-1R+PD-L1 MAb - solid tumorssolid tumors RG7446 PD-L1 MAb + Gazyva – lymphoma 2NMEs transitioned from Ph1 RG6046 SERD ER-pos (HER2-neg) mBC CHU: URAT 1 inh - gout 5 AIs RG3502 Kadcyla – HER2-pos advanced NSCLC RG435 Avastin + Tarceva - EGFR mutpos. NSCLC RG6062 Esbriet – ILD, systemic sclerosis related RG7421 cobimetinib – triple negative breast cancer RG7601 venetoclax (Bcl-2-inh)+ Rituxan - rel/ref follicular lymphoma 3 AIs RG7601 venetoclax (Bcl-2 inh)+ Gazyva - CLL 1st line RG7446 PD-L1 bladder cancer 2nd line CHU Actemra – large-vessel vasculitis (added by Chugai) 1 AI following EU submission RG105 MabThera – CLL subcutaneous formulation Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration 1 AI removed by Chugai Suvenyl - enthesopathy 1 AI following US approval RG435 Avastin - rel. ovarian ca. Ptresistant 3 NMEs RG7666 PI3K inh - glioblastoma 2L RG7624 IL-17 MAb - autoimmune diseases RG7458 MUC16 ADC - ovarian and pancreatic cancer Status as of January 28, 2015 6 NMEs RG7593 pinatuzumab vedotin (CD22 ADC) - heme tumors RG7449 quilizumab - asthma RG7128 mericitabine - HCV RG1512 inclacumab - ACS/CVD RG1578 decoglurant (mGluR2 NAM) depression RG7597 HER3/EGFR DAF m. epithelial tumors 79 Roche Group development pipeline Phase I (33 NMEs + 11 AIs) Oncology RG6016 LSD1 inh RG6047 SERD (2) RG6061 Other disease areas AML RG7625 autoimmune diseases ER+(HER2-neg) mBC RG7880 - HIF1 alpha LNA solid tumors RG6080 DBO β-lactamase inh RG6078 IDO inh solid tumors RG7689 - RG7116 HER3 MAb solid tumors RG7795 TLR7 agonist RG7155 CSF-1R + PDL-1 MAb solid tumors RG7641 aldosterone synth inh met. diseases RG7304 Raf & MEK dual inh solid tumors RG7203 PDE10A inh schizophrenia RG7388 MDM2 ant solid & hem tumors RG7342 mGlu5 PAM schizophrenia RG7446 PD-L1 MAb+Tarceva RG7345 TAUpS422 MAb RG7446 PD-L1 MAb+Zelboraf+/-cobimetinib m. melanoma RG7410 TAAR1 ago schizophrenia RG7446 PD-L1 MAb+Avastin+chemo solid tumors RG7893 Nav1.7 inh pain RG7446 PD-L1 MAb+cobimetinib solid tumors RG7800 SMN2 splicer spinal muscular atrophy RG7446 PD-L1 MAb+ipi/IFN solid tumors RG7935 a-synuclein MAb RG7446 PD-L1 MAb solid tumors RG3645 Lucentis sust. deliv. RG7446 PD-L1 MAb+Gazyva lymphoma RG7716 VEGF-ANG2 MAb RG7450 Steap 1 ADC RG7597 NSCLC EGFR+ prostate ca. HER3/EGFR DAF+ cobi KRAS+ s. tumors RG7601 venetoclax (Bcl-2)+ Gazyva CLL RG7601 venetoclax (Bcl-2) RG7741 ChK1 inh RG7775 MDM2 (4) IV prodrug RG7787 MSLN PE cFP solid tumors RG7802 RG7813 CEA CD3 TCB CEA IL2v solid tumors solid tumors RG7841 RG7842 ADC solid tumors ERK inh solid tumors RG7876 RG7882 CD40 iMAb+PD-L1 MAb solid tumors ADC ovarian ca RG7888 OX40 MAb heme indications solid tum & lymphoma Status as of January 28, 2015 AML solid tumors CLL autoimmune diseases bact. infections infectious diseases HBV Alzheimer’s Parkinson's Disease AMD/RVO/DME wAMD New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche Genentech managed CHU Chugai managed 80 Roche Group development pipeline Phase II (23 NMEs + 12 Als) Phase III (9 NMEs + 21 Als) Registration (1 NME + 4 Als) EGFR mut+ NSCLC RG4351 Avastin glioblastoma 1st line RG105 MabThera SC HER2+ NSCLC RG4351 Avastin ovarian cancer 1st line RG4352 Avastin recurrent cervical cancer hemophilia A RG4351 Avastin rel. ovarian ca. Pt-sensitive RG12732 Perjeta HER2+ BC neoadj ER+(HER2-neg) mBC RG435 Avastin NSCLC adj RG7421 cobimetinib + Zelboraf 2nd RG36453 Lucentis RG435 RG3502 Avastin+Tarceva RG6013 FIXa /FX bispecific MAb RG6046 SERD RG7155 CSF-1R MAb RG7221 Ang2-VEGF MAb Kadcyla PVNS/solid tumors RG1273 Perjeta colorectal cancer RG1273 Perjeta pictilisib solid tumors RG7421 RG7440 cobimetinib ipatasertib (AKT inh) TNBC solid tumors RG1273 RG3502 Perjeta HER2+ gastric cancer 1st line Kadcyla HER2+ gastric cancer 2nd line RG3502 Kadcyla +/- Perjeta HER2+ mBC 1st l RG7446 PD-L1 MAb RG3502 Kadcyla RG7446 PD-L1 MAb + Avastin RCC RG3502 Kadcyla + Perjeta HER2+ BC adj RG7446 PD-L1 MAb bladder cancer 1/2l RG3502 Kadcyla + Perjeta HER2+ BC neoadj RG7596 polatuzumab vedotin (CD79bADC) hem tumors RG7159 Gazyva ADC RG7599 lifastuzumab vedotin (NaPi2bADC)Pt-resist. OC RG7159 Gazyva iNHL rituximab refractory RG7601 venetoclax (Bcl-2) C LL rel/refract 17pdel RG7159 Gazyva follicular lymphoma 1st line RG7601 venetoclax (Bcl-2) DLBCL RG7204 Zelboraf rel/ref FL liver cancer systemic sclerosis RG7446 RG7446 RG7601 RG7601 PD-L1 MAb NSCLC 2nd line PD-L1 MAb bladder cancer 2nd line venetoclax (Bcl-2) + Rit. CLL rel/ref venetoclax+Gazyva (Bcl-2) CLL 1st line IPF RG7853 alectinib (ALK inhibitor) lebrikizumab SSc Esbriet idiopathic – interstitial pulmonary lung disease fibrosis RG1569 Actemra IL-31R MAb RG3637 RG7413 lebrikizumab etrolizumab pictilisib RG7321 NSCLC 2nd/3rd line RG7601 venetoclax (Bcl-2)+ Rituxan RG7604 taselisib (mutant-selective) RG7686 RG1569 glypican-3 MAb Actemra RG3637 lebrikizumab RG3637 RG6062 CHU solid tumors atopic dermatitis RG7227 danoprevir HCV RG7745 RG7790 RG7929 Flu A MAb setrobuvir influenza HCV RG7929 LptD antibiotic RG7697 GIP/GLP-1 dual ago CHU RG1577 URAT 1 inh MAO-B inh RG1662 RG1678 GABRA5 NAM Down Syndrome bitopertin obsessive compulsive dis. RG7090 RG7314 RG7412 basimglurant (mGlu5 NAM) TRD V1 receptor antag autism crenezumab Alzheimer’s antibacterial type 2 diabetes gout Alzheimer’s CHU Actemra CHU IL-6R MAb HER2+ mBC line CLL m. melanoma diabetic retinopathy HER2+ BC adj HER2+ BC adj 1 2 3 US only : FDA submission decision pending Approved in US, submitted in EU Submitted in US DLBCL 1st line melanoma adj NSCLC giant cell arteritis severe asthma ulcerative colitis large-vessel vasculitis neuromyelitis optica RG1450 RG1594 gantenerumab ocrelizumab RG1594 ocrelizumab RG7417 lampalizumab (factor D) Status as of January 28, 2015 Alzheimer’s RMS PPMS geo. atrophy New Molecular Entity (NME) Additional Indication (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche Genentech managed CHU Chugai managed RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU 81 NME submissions and their additional indications Projects currently in phase 2 and 3 gantenerumab (RG1450) Alzheimer‘s SERD (RG6046) cobimetinib (MEK inh) combo Zelboraf met melanoma ER+(HER2-neg) mBC MAO-B inh (RG1577) Alzheimer‘s FIXa /FX bispecific MAb (RG6013) hemophilia A GABRA5 NAM (RG1662) Down syndrome CSF-1R MAb (RG7155) PVNS and solid tumors bitopertin (RG1678) obsessive compulsive dis. Ang2-VEGF MAb (RG7221) colorectal cancer basimglurant (RG7090) depression ipatasertib AKT inh (RG7440) solid tumors V1 receptor antag (RG7314) autism polatuzumab vedotin (RG7596) CD79b ADC heme tumors crenezumab (RG7412) Alzheimer‘s idiopathic pulmonary fibrosis ocrelizumab (RG1594) PPMS pictilisib PI3K inh (RG7321) solid tumors cobimetinib TNBC etrolizumab (RG7413) ulcerative colitis lebrikizumab (RG3637) severe asthma lifastuzumab (RG7599) NaPi2b ADC Pt resistant OC PDL-1 MAb (RG7446) combo Avastin RCC lampalizumab anti-factor D (RG7417) geo atrophy PDL-1 MAb (RG7446) bladder cancer (mutant-selective) solid tumors taselisib (PI3Ki, RG7604) venetoclax (Bcl-2i, RG7601) + Rituxan rel/ref FL danoprevir* (RG7227) HCV PD-L1 MAb (RG7446) NSCLC 2nd/3rd line glypican-3 Mab (RG7686) liver cancer venetoclax (Bcl-2i, RG7601) + Gazyva CLL 1st line Flu A MAb (RG7745) influenza ocrelizumab (RG1594) RMS venetoclax (Bcl-2i, RG7601) CLL rel/ref alectinib (RG7853) ALK-pos. NSCLC venetoclax (Bcl-2i, RG7601) + Gazyva DLBCL LptD antibiotic (RG7929) antibacterial 2015 2016 2014 Unless stated otherwise, submissions are planned to occur in US and EU * lead market China Status as of January 28, 2015 lebrikizumab (RG3637) 2017 and beyond Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 82 Submissions of additional indications for existing products Projects currently in phase 2 and 3 Gazyva iNHL rituximab refractory Gazyva follicular lymphoma 1st line Zelboraf melanoma adj. Perjeta HER2-pos. gastric cancer 1L *Avastin (US) ovarian cancer 1st line Kadcyla+Perjeta HER2-pos. BC neoadj Kadcyla HER2-pos. NSCLC Lucentis (US) diabetic retinopathy *Avastin (US) rel. ovarian ca. Pt-sens MabThera SC (EU) CLL Avastin +Tarceva(EU) EGFR mut+ NSCLC Gazyva DLBCL 1st line Kadcyla+Perjeta HER2-pos. BC adj Avastin (US) GBM Perjeta HER2-pos. mBC 2ndline Kadcyla HER2-pos. BC adj Kadcyla +/- Perjeta HER2-pos mBC 1st line Perjeta HER2-pos. BC adj Avastin NSCLC adj Kadcyla HER2-pos gastric cancer 2L Actemra giant cell arteritis Actemra systemic sclerosis 2016 2017 and beyond **Perjeta (EU) HER2-pos. BC neoadj *Avastin (US) rel. ovarian ca. Pt-resist **Avastin (EU) cervical cancer recurrent 2014 2015 Indicates submission to health authorities has occurred. * approved in EU; ** approved in US Unless stated otherwise, submissions are planned to occur in US and EU. Status as of January 28, 2015 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 83 Major granted and pending approvals 2014 Pending approvals Approved Avastin rel. ovarian ca. Pt-resist November 2014 Esbriet* idiopathic pulmonary fibrosis October 2014 Avastin cervical cancer August 2014 Xolair chronic idiopathic urticaria March 2014 cobimetinib + Zelboraf m. melanoma Filed December 2014 MabThera NHL sc formulation March 2014 RoActemra RA sc formulation April 2014 Avastin cervical cancer Filed April 2014 Gazyvaro CLL July 2014 RoActemra early RA September 2014 Perjeta BC neoadjuvant Filed September 2014 Avastin rel. ovarian ca. Pt-resist August 2014 Esbriet* idiopathic pulmonary fibrosis March 2011 cobimetinib + Zelboraf m. melanoma Filed September 2014 US EU Lucentis diabetic retinopathy Filed August 2014 MabThera SC CLL Filed November 2014 Japan-Chugai alectinib ALECENSA ALK-pos rec/adv NSCLC July 2014 Zelboraf m. melanoma December 2014 Oncology Immunology Infectious Diseases CardioMetabolism Status as of January 28, 2015 * Newly acquired asset (Intermune) Neuroscience Ophthalmology Other NME 84 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 85 Avastin Ovarian cancer clinical development programme Front-line metastatic ovarian cancer Indication Phase/study Phase III GOG-0218 Phase III ICON7 # of patients N=1,873 N=1,528 Design ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months) ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) ARM A: Paclitaxel and carboplatin for 6 cycles ARM B: Paclitaxel and carboplatin plus concurrent Avastin for 6 cycles followed by Avastin alone for up to 18 cycles (12 months) Avastin dose 15 mg/kg q3 weeks 7.5 mg/kg q3 weeks Primary endpoint Progression-free survival Progression-free survival Status Study met its primary endpoint in Q1 2010 Data presented at ASCO 2010 and 2011 Results: NEJM 2011 Dec 29;365(26):2484-96 Study met its primary endpoint Q3 2010 Data presented at ESMO 2010 and ASCO 2011 Results: NEJM 2011 Dec 29;365(26):2473-83 OS data presented at ECC 2013 EMA approval granted Q4 2011 Re-evaluate FDA submission in 2015 ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology 86 Avastin Ovarian cancer clinical development programme Relapsed platinum-sensitive ovarian cancer Relapsed platinum-resistant ovarian cancer Phase/study Phase III OCEANS Phase III AURELIA # of patients N=484 N=361 Indication Design ARM A: Carboplatin, gemcitabine, and concurrent ARM A: Paclitaxel, topotecan or liposomal placebo for 6-10 cycles, followed by placebo alone doxorubicin until disease progression ARM B: Paclitaxel, topotecan or liposomal ARM B: Carboplatin, gemcitabine, and concurrent doxorubicin plus Avastin Avastin for 6-10 cycles, followed by Avastin alone until disease progression. Avastin dose 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks Primary endpoint Progression-free survival Progression-free survival Status Study met its primary endpoint Q1 2011 EMA approval granted Q4 2012 Final data presented at SGO 2014 Re-evaluate FDA submission in 2015 Study met its primary endpoint Q2 2012 Data presented at ASCO 2012 Results published in JCO 2014 May 1;32(13):130916 EMA approval granted Q3 2014 FDA approval granted Q4 2014 ASCO=American Society of Clinical Oncology; SGO=Society of Gynecologic Oncology; JCO=Journal of Clinical Oncology 87 Avastin Cervical and brain cancer clinical development programmes Indication Stage IVB, recurrent or persistent cervical cancer Newly diagnosed glioblastoma Phase/study Phase III GOG-240 Phase III AVAglio # of patients N=452 N=920 Design ARM A: Paclitaxel, cisplatin ARM B: Paclitaxel, cisplatin plus Avastin ARM C: Paclitaxel, topotecan ARM D: Paclitaxel, topotecan plus Avastin Avastin dose 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks Primary endpoint Overall survival Progression-free survival Overall survival Status Study met its primary endpoint Q1 2013 Results published in NEJM Feb. 2014; 370(8):734-43 Filed globally Q2 2014 FDA approval granted Q3 2014 Co-primary endpoint of PFS met Q3 2012 Overall survival data presented at ASCO 2013 Filed in EU Q1 2013 Negative CHMP opinion Q3 2014 US filing pending TMZ=temozolomide ASCO=American Society of Clinical Oncology ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression 88 Avastin Lung and breast cancer development programmes Indication Adjuvant lung cancer First-line HER2-negative metastatic breast cancer Phase/study Phase III ECOG 1505 Phase III MERiDiAN # of patients N=1,500 N=480 Design Avastin dose Primary endpoint Status ARM A: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed ARM B: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months ARM A: Paclitaxel + Avastin ARM B: Paclitaxel + Placebo 15 mg/kg q3 weeks 10 mg/kg q2 weeks Overall survival PFS in ITT PFS in patients with high plasma VEGF-A Recruitment completed Q4 2013 Expect data in 2016 Recruitment completed Expect data in 2015 89 Erivedge A novel small molecule inhibitor of the hedgehog signaling pathway Locally advanced or metastatic basal cell carcinoma Idiopathic pulmonary fibrosis Phase/study Phase II STEVIE Phase II # of patients N=1,200 N=129 Indication In collaboration with Curis Design Single ARM: 150 mg Erivedge orally once daily ARM A: Erivedge 150mg daily ARM B: placebo Primary endpoint Safety: Incidence of adverse events Change in forced vital capacity (FVC) Status FPI Q2 2011 FPI pending in anticipation of trial design amendment to incorporate new standard of care pirfenidone. 90 Esbriet Small molecule with activity in fibrotic diseases Indication In collaboration with Curis Systemic sclerosis-related interstitial lung disease (SSc-ILD) Phase/study Phase II LOTUSS # of patients N=63 Design Primary endpoint Safety Status LPI Q3 2014 Data to be presented in 2015 Open-label, randomized, parallel-group, safety and tolerability study 2 week vs. 4 week dose titration regimens 91 Gazyva/Gazyvaro Type II, glycoengineered anti-CD20 monoclonal antibody Previously untreated or relapsed/refractory chronic lymphocytic leukemia Diffuse large B-cell lymphoma (DLBCL) Phase/study Phase III GREEN Phase III GOYA # of patients N=800 N=1,418 Indication Design Single-arm cohort study: Gazyva alone or in ARM A: Gazyva 1000mg IV plus CHOP combination with different chemotherapy ARM B: MabThera/Rituxan plus CHOP regimens (FC, Bendamustin or Clb), investigation of different strategies to reduce IRRs Primary endpoint Safety in combination with different chemotherapy regimens Progression-free survival Status FPI Q4 2013 Initial safety data presented at ASH 2014 Recruitment completed Q2 2014 Expect data in 2015 In collaboration with Biogen Idec ASH=American Society of Hematology 92 Gazyva/Gazyvaro Type II, glycoengineered anti-CD20 monoclonal antibody Indication Indolent non-Hodgkin’s lymphoma MabThera/Rituxan refractory Front-line indolent non-Hodgkin’s lymphoma Phase/study Phase III GADOLIN Induction and maintenance study Phase III GALLIUM Induction and maintenance study # of patients N=411 N=1,401 Design ARM A: Gazyva 1000mg iIV plus bendamustine followed by Gazyva mainteinance ARM B: bendamustine ARM A: Gazyva 1000mg IV plus chemotherapy followed by Gazyva maintenance ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance Chemotherapy: For follicular lymphoma: CHOP, CVP or bendamustine For non-follicular lymphoma: physician’s choice Primary endpoint Progression-free survival Progression-free survival Status LPI Q4 2014 Expect data in 2017 Recruitment completed Expect data in 2017 In collaboration with Biogen Idec CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone 93 Kadcyla Evaluating new treatment options in HER2-positive early breast cancer HER2-positive neoadjuvant breast cancer HER2-positive early breast cancer high-risk patients Operable HER2-positive early breast cancer Phase/study Phase III KRISTINE Phase III KATHERINE Phase III KAITLIN # of patients N=432 N=1,484 N=2,500 Indication Design Before surgery patients will ARM A: Kadcyla 3.6mg/kg q3w Following surgery and receive 6 cycles of: ARM B: Herceptin antracycline-based therapy: ARM A: Herceptin plus Perjeta ARM A: Herceptin 6mg/kg q3w plus docetaxel plus carboplatin plus Perjeta 420 mg/kg q3w ARM B: Kadcyla plus Perjeta plus taxane ARM B: Kadcyla 3.6mg/kg q3w After surgery patients will plus Perjeta 420mg/kg q3w receive: ARM A: Herceptin plus Perjeta ARM B: Kadcyla plus Perjeta Primary endpoint Pathologic Complete Response Invasive disease-free survival (pCR) (IDFS) Invasive disease-free survival (IDFS) Status FPI Q2 2014 FPI Q1 2014 In collaboration with ImmunoGen, Inc. FPI Q1 2013 94 Kadcyla Evaluating new treatment options in HER2-positive breast and gastric cancer Previously untreated HER2 pos. metastatic breast cancer Previously treated locally advanced or metastatic HER2-positive gastric cancer HER2-positive advanced (2L+) NSCLC Phase/study Phase III MARIANNE Phase II/III GATSBY Phase II # of patients N=1,092 N=412 N=40 Indication Design ARM A: Herceptin plus taxane ARM A: Kadcyla 3.6mg/kg q3w ARM B: Kadcyla 3.6mg/kg q3w plus ARM B: Kadcyla 2.4mg/kg weekly Perjeta ARM C: docetaxel or paclitaxel ARM C: Kadcyla 3.6 mg/kg q3w plus placebo Primary endpoint Status Progression-free survival assessed by IRF Phase II: Dose-finding Phase III: Overall survival Recruitment completed Q2 2012 FPI Q3 2012 Study met non-inferiority endpoint, showing similar progression-free survival (PFS) among the three arms Q4 2014 Study did not meet PFS superiority endpoint for Kadcyla-containing regimens Q4 2014 In collaboration with ImmunoGen, Inc. Single-agent Kadcyla 3.6 mg/kg Overall response rate and safety FPI Q4 2014 95 MabThera/Rituxan Oncology development programme Indication Previously untreated chronic lymphocytic leukemia Phase/study Phase Ib SAWYER Subcutaneous study Study being conducted ex-US # of patients N=225 Design Two-stage design: - Stage 1 (dose-finding, N=55) - Stage 2 (N=170): CLL dose confirmation: ARM A: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) ARM B: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide) Primary endpoint Status Part 1: PK (dose selection) Part 2: PK of MabThera IV versus MabThera SC (arm A vs. arm B) Stage 2 data confirmed non-inferior PK and comparable safety/efficacy of MabThera 1600mg SC vs. MabThera IV Presented at ASH 2014 Filed in EU Q4 2014 Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme ASH=American Society of Hematology 96 Perjeta First in a new class of HER dimerization inhibitors Indication Adjuvant HER2-positive breast cancer Neoadjuvant HER2-positive breast cancer Phase/ study Phase II NEOSPHERE Phase II TRYPHAENA Phase III APHINITY # of patients N=417 N=225 N=4,803 Design Primary endpoint Status ARM A: Herceptin plus docetaxel ARM B: Perjeta (840mg loading, 420mg q3w) plus Herceptin and docetaxel ARM C: Perjeta plus Herceptin ARM D: Perjeta plus docetaxel Pathologic complete response (pCR) Positive data presented at SABCS 2010 Biomarker data presented SABCS 2011 ARM A: FEC followed by Taxane with Herceptin and pertuzumab (H+P given concurrently) ARM B: FEC followed by Taxane with Herceptin + pertuzumab (H+P given sequentially) ARM C: TCH + pertuzumab (H+P given concurrently) ARM A: Perjeta (840mg loading, 420 q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles) ARM B: placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles) Safety Invasive disease-free survival (IDFS) Positive safety and efficacy data presented at SABCS 2011 Recruitment completed Q3 2013 Expect data in 2016 FDA approval granted Q3 2013 Filed in EU Q3 2014 FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; SABCS=San Antonio Breast Cancer Symposium. 97 Perjeta First in a new class of HER dimerization inhibitors Indication Phase/ study # of patients Design Second-line HER2positive metastatic breast cancer Advanced HER2-positive gastric cancer Neoadjuvant/adjuvant HER2-positive breast cancer Phase III PHEREXA Phase III JACOB Phase II BERENICE N=450 N=780 N=400 ARM A: Perjeta (840mg loading, 420mg q3w) plus Herceptin and chemotherapy ARM B: placebo plus Herceptin and chemotherapy Neoadjuvant treatment: ARM A: ddAC q2w x4 cycles followed by weekly paclitaxel for 12 weeks, with P+H x4 cycles ARM B: FEC+P+H x4 cycles followed by docetaxel+P+H x4 cycles ARM A: Herceptin plus Xeloda ARM B: Perjeta plus Herceptin and Xeloda Adjuvant treatment: P+H q3w to complete 1 year of HER2 therapy Hormonal and radiation therapy as indicated Primary endpoint Status Progression-free survival Overall survival Safety Recruitment completed Q3 2013 Expect data in 2015 FPI Q2 2013 FPI Q3 2014 ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide 98 Zelboraf A selective novel small molecule that inhibits mutant BRAF Indication Adjuvant therapy in patients with resected cutaneous BRAF mutation positive melanoma Phase/study Phase III BRIM8 # of patients N=725 Design 52-week treatment ARM A: Zelboraf 960mg bid ARM B: Placebo Primary endpoint Disease-free survival Status FPI Q3 2012 In collaboration with Plexxikon, a member of Daiichi Sankyo Group See also combinations with: cobimetinib (MEK inhibitor) and anti-PDL1 (RG7446) 99 Actemra/RoActemra Interleukin 6 receptor inhibitor Indication Systemic sclerosis Giant Cell Arteritis Phase/study Phase II faSScinate Proof-of-concept study Phase III GiACTA # of patients N=86 N=250 Design Blinded 48-week treatment with weekly dosing: ARM A: Actemra SC 162mg ARM B: Placebo SC Open-label weekly dosing at weeks 49 to 96: Actemra SC 162mg Part 1: 52-week blinded period ARM A: Actemra SC 162mg qw + 26 weeks prednisone taper ARM B: Actemra SC 162mg q2w + 26 weeks prednisone taper ARM C: Placebo+ 26 weeks prednisone taper ARM D: Placebo+ 52 weeks prednisone taper Primary endpoint Status Part II: 104-week open label extension – patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw Change in modified Rodnan skin score (mRSS) at week Proportion of patients in sustained remission at week 52 24 Safety 48 week data presented at ACR 2014 Primary and all key secondary endpoints showed trend for improved efficacy In collaboration with Chugai ACR=American College of Rheumatology FPI Q3 2013 100 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 101 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase ALK-positive crizotinib-naïve advanced NSCLC ALK-positive advanced NSCLC after progression on crizotinib treatment ALK-positive advanced NSCLC after progression on crizotinib treatment Treatment naïve ALKpositive advanced NSCLC Phase/study Phase I/II AF-001JP Japanese study Phase I/II AF-002JG/NP28761 US study Phase I/II ACCALIA/NP28673 Phase III ALEX # of patients N=70 Phase I: N=36 Phase II: N=85 N=130 N=286 Indication Design Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 ARM A: alectinib 600mg BID ARM A: crizotinib 250mg BID Primary endpoint Phase I: Determination of recommended dose Phase II: Safety and efficacy Phase I: Determination of recommended dose Phase II: Safety and efficacy Phase I: Determination of recommended dose Phase II: Safety and efficacy Progression-free survival Status Results published in Lancet Oncology 2013 Jun;14(7):5908 Approved in Japan with brand name ALECENSA July 2014 FPI Q3 2014 Phase I data presented at ECC Phase II FPI Q3 2013 2013 Phase I full cohort including CNS data published in Lancet Oncology 2014, Sept.15(10):1119-28 Phase II FPI Q3 2013 In collaboration with Chugai ECC=European Cancer Congress Breakthrough therapy designation granted by the FDA June 2013 102 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Metastatic NSCLC 2nd line Locally advanced or metastatic NSCLC PD-L1 positive Locally advanced or metastatic NSCLC PD-L1 positive Locally advanced or metastatic NSCLC (2nd/3rd line) Non-small cell lung cancer Phase/study Phase III OAK Phase II FIR Phase II BIRCH Phase II POPLAR Phase I # of patients N=1100 N=130 N=635 N=287 N=32 Indication Design RG7446 1200mg q3w Single arm study Single arm study ARM A: RG7446 docetaxel RG7446 1200mg q3w RG7446 1200mg q3w 1200mg q3w ARM B: Docetaxel RG7446 plus Tarceva1 Primary endpoint Overall survival Overall response rate Objective response rate Overall survival Safety Status FPI Q1 2014 Recruitment completed Q2 2014 Recruitment completed Q2 2014 FPI Q1 2014 1Tarceva Recruitment completed Q4 2014 is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC; 103 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Locally advanced or metastatic urothelial bladder cancer Locally advanced or metastatic urothelial bladder cancer Untreated advanced renal cell carcinoma Phase/study Phase III Phase II Phase II # of patients N=767 N=330 N=150 Indication Design Patients who progressed on at RG7446 1200mg q3w least one platinum-containing Cohort 1: Treatment-naive regimen will receive: and cisplatin-ineligible ARM A: RG7446 1200mg q3w patients ARM B: chemotherapy Cohort 2: Patients with (vinflunine, paclitaxel or disease progression following docetaxel) or during platinum-containing treatment ARM A: RG7446 plus Avastin ARM B: RG7446; following PD: RG7446 plus Avastin ARM C: sunitinib; following PD: RG7446 plus Avastin Primary endpoint Overall survival Objective response rate Progression free survival Status FPI January 2015 FPI Q2 2014 FPI Q1 2014 104 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Solid tumors Solid tumors Locally advanced or metastatic solid tumors Relapsed/Refractory follicular lymphoma and DLBCL Phase/study Phase I Phase I Phase I Phase I # of patients N=160 N=110 N=200 N=52 Part 1: sequential administration of RG7446 and RG7876 (CD40 iMAb) Part 2: concomitant administration of RG7446 and RG7876 Part 3: study drugs schedule in specific indication per Part 2 RG7446 in combination with RG7155 (anti-CSF1R) Part 1: dose escalation Part 2: expansion Indication Design ARM A: RG7446 plus ipilimumab ARM B: RG7446 plus interferon alpha-2b Stage 1: safety evaluation RG7446 plus Gazyva Stage 2: expansion RG7446 plus Gazyva Primary endpoint Safety Safety Safety Safety Status FPI Q4 2014 FPI January 2015 FPI Q3 2014 FPI Q4 2014 105 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Solid tumors Previously untreated metastatic melanoma BRAF mutation positive Locally advanced or metastatic tumors Solid tumors Phase/study Phase I Phase I Phase I Phase I # of patients N=180 N=44 N=90 N=344 Indication Design Primary endpoint Safety/PK Safety/PK Status FPI Q2 2012 FPI Q4 2012 1Zelboraf ARM A: RG7446 + Avastin Dose-finding study of ARM B: RG7446 + Avastin RG7446 (anti-PDL1) + + FOLFOX Zelboraf1 and RG7446 (anti ARM C: RG7446 + Avastin PDL1) + Zelboraf1 + + carboplatin+paclitaxel cobimetinib combinations ARM D: RG7446 + Avastin + carboplatin+ pemetrexed ARM E: RG7446 + Avastin + carboplatin+ nab-paclitaxel in collaboration with Plexxikon, a member of Daiichi Sankyo Group; in collaboration with Exelixis 2Cobimetinib ARM A: Dose-finding – RG7446 plus cobimetinib2 ARM B: Dose-expansion RG7446 plus cobimetinib Dose escalation study Safety Safety/PK FPI Q4 2013 FPI Q2 2011 Initial efficacy data presented at ASCO 2013 Updated data presented at ECC 2013 Data from bladder cohort presented at ASCO and ESMO 2014 106 Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogenactivated protein kinase kinase Previously untreated metastatic melanoma BRAF mutation positive First-line metastatic triple negative breast cancer Phase/study Phase III coBRIM Phase II # of patients N=495 N=112 Indication Design ARM A: Zelboraf1 plus cobimetinib ARM B: Zelboraf1 plus placebo ARM A: cobimetinib plus paclitaxel ARM B: placebo plus paclitaxel Primary endpoint Progression-free survival Progression-free survival, safety Status FPI January 2015 Primary endpoint met Q3 2014 Data presented at ESMO and SMR 2014 Results published NEJM 2014 Nov 13;371(20):1867-76 Filed in EU Q3 2014 Filed in US Q4 2014 In collaboration with Exelixis 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; ESMO=European Society for Medical Oncology; SMR=Society for Melanoma Research; NEJM=New England Journal of Medicine 107 Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogenactivated protein kinase kinase Locally advanced or metastatic tumors Previously untreated metastatic melanoma BRAF mutation positive Locally advanced or metastatic tumors with mutant KRAS Phase/study Phase I Phase I Phase I # of patients N=90 N=44 N=50 Indication Design ARM A: Dose-finding Dose-finding study of cobimetinib plus RG7446 (anti- RG7446+Zelboraf1 and PDL1) RG7446+Zelboraf1+ ARM B: Dose-expansion cobimetinib combinations cobimetinib plus RG7446 (antiPDL1) Primary endpoint Safety Status FPI Q4 2013 Dose finding of cobimetinib plus RG7597 (anti-HER3/EGFR DAF) Safety/PK Safety FPI Q4 2012 FPI Q4 2013 In collaboration with Exelixis 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group 108 Pictilisib (RG7321, GDC-0941) Pan-PI3 kinase inhibitor with potential activity in multiple cancers Indication 2L ER-positive metastatic breast cancer Previously untreated advanced or recurrent NSCLC Locally recurrent or metastatic HER2-negative HR-positive breast cancer Phase II FERGI Phase II FIGARO Phase II PEGGY N=340 N=302 N=180 Phase # of patients Design ARM A: pictilisib plus hormonal therapy ARM B: apitolisib plus hormonal therapy (ARM B discontinued) ARM C: Hormonal therapy + placebo ARM A: pictilisib + carboplatin + paclitaxel ARM B: placebo + carboplatin + paclitaxel ARM C: pictilisib+ carboplatin + paclitaxel + Avastin ARM D: placebo + carboplatin + paclitaxel + Avastin Primary endpoint Progression-free survival Status Recruitment completed Q1 2014 Data presented at SABCS 2014 ARM A: pictilisib + paclitaxel ARM B: placebo + paclitaxel Progression-free survival Progression-free survival FPI Q1 2012 Recruitment completed Q2 2014 109 Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies Indication Phase # of patients Design Non-Hodgkin's lymphoma Non-Hodgkin’s lymphoma Relapsed or Refractory follicular lymphoma and DLBCL Phase II ROMULUS Phase Ib Phase Ib/II N=120 N=90 N=224 ARM A: pinatuzumab vedotin plus Rituxan ARM B: polatuzumab vedotin plus Rituxan ARM C: polatuzumab vedotin plus Gazyva Primary endpoint Status Safety and anti-tumor activity Recruitment completed Q1 2014 Pinatuzumab vedotin portion of the study completed Updated data presented at ASH 2014 FPI in Gazyva arm expected in Q1 2015 Dose escalation study in combination with Rituxan and chemotherapy Safety Safety FPI Q4 2013 FPI Q4 2014 In collaboration with Seattle Genetics ASH=American Society of Hematology; BR=bendamustine and Rituxan PIb: dose escalation P2: polatuzumab vedotin + BR vs. BR P2 expansion: polatuzumab vedotin +Gazyva non-randomised 110 Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor targeting commonly mutated oncogene Indication HER2-negative ER-positive metastatic breast caner patients who progressed after aromatase inhibitor therapy Neoadjuvant HER2-negative ERpositive breast cancer Phase III SANDPIPER Phase II LORELEI N=600 N=330 Phase # of patients Design ARM A: taselisib plus Fulvestrant ARM B: placebo plus Fulvestrant ARM A: taselisib plus letrozole ARM B: placebo plus letozole Primary endpoint Progression-free survival Response rate and pCR Status Expect FPI Q1 2015 FPI Q4 2014 111 Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor targeting commonly mutated oncogene Indicationx Solid tumors and HER2-negative HR-positive breast cancer HER2-negative HR-positive locally recurrent or metastatic breast cancer PI3KCAmut-pos. 2L squamous NSCLC Lung Master Protocol Phase I/II Phase I Phase II Lung-MAP N=320 N=65 N=120 Phase # of patients Design Phase I taselisib taselisib plus letrozole or fulvestrant Phase II taselisib (multiple doses) plus letrozole or fulvestrant Primary endpoint Status taselisib plus docetaxel taselisib plus paclitaxel taselisib vs. chemo Safety/PK/efficacy Safety Progression-free survival Recruitment completed Q2 2014 Updated data presented at SABCS 2014 FPI Q2 2013 FPI Q2 2014 SABCS=San Antonio Breast Cancer Symposium 112 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Relapsed or Refractory CLL Untreated CLL patients with coexisting medical conditions Relapsed or Refractory CLL with 17p deletion Phase/study Phase III MURANO Phase III CLL14 Phase II # of patients N=370 N=432 N=100 Indication Design ARM A: venetoclax plus Rituxan ARM B: Rituxan plus bendamustine Primary endpoint Status ARM A: venetoclax plus Gazyva ARM B: chlorambucil plus Gazyva Single-agent venetoclax Progression-free survival Progression-free survival Safety/MTD FPI Q1 2014 FPI Q4 2014 Recruitment completed Q2 2014 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma ASCO=American Society of Clinical Oncology 113 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or Refractory CLL Relapsed CLL and SLL Relapsed or Refractory or previously untreated CLL Relapsed or Refractory or previously untreated CLL Phase II Phase Ib Phase Ib Phase Ib N=40 N=50 N=70 N=74 Phase/stud y # of patients Design Primary endpoint Status venetoclax after ibrutinib therapy venetoclax after idelalisib therapy Dose-escalation study in combination with MabThera/Rituxan venetoclax in combination venetoclax in combination with MabThera/Rituxan with Gazyva and bendamustine Overall response rate Safety/MTD Safety/MTD Safety/MTD FPI Q3 2014 FPI Q3 2012 Data presented at ASCO 2014 FPI Q2 2013 FPI Q1 2014 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma ASCO=American Society of Clinical Oncology 114 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Relapsed or Refractory follicular non-Hodgkin’s lymphoma Front-line DLBCL Relapsed or Refractory NHL Relapsed or Refractory CLL and NHL Phase/study Phase II Phase I/II Phase I Phase I # of patients N=156 N=230 N=40 N=211 Indication Design ARM A: venetoclax plus Rituxan ARM B: venetoclax plus Rituxan plus bendamustine ARM C: Rituxan plus bendamustine Dose finding: ARM A: venetoclax+RCHOP ARM B: venetoclax+GCHOP Dose escalation of venetoclax in combination with Rituxan and bendamustine Dose-escalation study Expansion: venetoclax+R/G-CHOP Primary endpoint Overall response rate Safety and efficacy Safety/MTD Safety/PK/Response rate Status FPI Q4 2014 FPI Q2 2014 FPI Q2 2012 Study resumed Q3 2013 FPI Q2 2011 Updated CLL, SLL and NHL (DLBCL and FL) data presented at ASCO 2014 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 115 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Indication Relapsed or refractory multiple myeloma Acute myelogenous leukemia (AML) Phase/study Phase I Phase I Phase II Phase Ib # of patients N=30 N=30 N=54 N=89 Design Primary endpoint Safety/MTD Status FPI Q4 2012 Patients receiving Dose escalation cohort Bortezomib and Safety expansion cohort Dexamethasone as standard therapy: Dose escalation cohort: venetoclax+bortezomib+de xamethasone Safety expansion cohort: venetoclax+bortezomib+de xamethasone Dose escalation of venetoclax Safety/MTD Overall response rate Safety FPI Q4 2012 FPI Q4 2013 Data presented at ASH 2014 FPI Q4 2014 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) venetoclax (dose escalation) +decitabine venetoclax (dose escalation) +azacitidine 116 Factor IXa/X bispecific (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A Indication Hemophilia A Phase/study Phase I Study in Japan Phase I/II Study in Japan # of patients N=82 N≈18 Design Enrolled 64 HVs and 18 patients Expansion study in patients from phase 1 Primary endpoint Exploratory efficacy and safety Exploratory efficacy and safety Status Recruitment completed Q2 2014 Data presented at ASH 2014 FPI Q3 2014 In collaboration with Chugai ASH=American Society of Hematology 117 Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI) Indication Obsessive-compulsive disorder Phase/study Phase II SKYLYTE # of patients N=99 Design 16-week treatment period Background therapy of selective serotonin reuptake inhibitors (SSRI) •ARM A: bitopertin daily (30 mg) •ARM B: bitopertin daily (10 mg) •ARM C: placebo Primary endpoint Change in total score on Yale-Brown Obsessive Compulsive Scale Status FPI Q4 2012 118 Gantenerumab (RG1450) Fully human monoclonal antibody against amyloid-beta Indication Prodromal Alzheimer’s Disease Mild Alzheimer’s Disease Phase/study Phase II/III SCarlet RoAD Phase III Marguerite Road # of patients N=799 N=1,000 Design 104-week subcutaneous treatment period ARM A: gantenerumab (225 mg) ARM B: gantenerumab (105 mg) ARM C: placebo 104-week subcutaneous treatment period ARM A: gantenerumab ARM B: placebo Primary endpoint Change in CDR-SOB at 2 years Sub-study: change in brain amyloid by PET at 2 years Change in ADAS-Cog and ADCS-ADL at 2 years (co-primary) Status FPI Q1 2014 Phase I PET data: Archives of Neurology 2012 Feb;69(2):198-207 Enrollment completed Q4 2013 Study discontinued due to futility Q4 2014 In collaboration with Morphosys CDR-SOB=Clinical Dementia Rating scale Sum of Boxes 119 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Indication Ulcerative colitis patients who are TNF naïve Phase/study Phase III HIBISCUS I Induction study Phase III HIBISCUS II Induction study Phase III GARDENIA Sustained remission study # of patients N=350 N=350 N=720 ARM A: etrolizumab 105mg SC q4w + adalimumab placebo ARM B: etrolizumab placebo + adalimumab ARM C: etrolizumab placebo + adalimumab placebo Time on treatment 54 weeks ARM A: etrolizumab 105mg SC q4w + placebo IV ARM B: placebo SC q4w + adalimumab SC Design ARM A: etrolizumab 105mg SC q4w + adalimumab placebo ARM B: etrolizumab placebo + adalimumab ARM C: etrolizumab placebo + adalimumab placebo Primary endpoint Induction of remission compared with Induction of remission compared with Proportion of patients in sustained placebo as determined by the Mayo placebo as determined by the Mayo clinical remission as determined by Clinic Score (MCS) at week 10 Clinic Score (MCS) at week 10 Mayo Clinic Score (MCS) at weeks 10, 30 and 54 Status FPI Q4 2014 FPI Q4 2014 FPI Q4 2014 120 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin UC patient who are TNF naïve and refractory or intolerant to immunosuppressant and/or corticosteroid treatment UC patient who are refractory or intolerant of TNF inhibitors Phase/study Phase III LAUREL Maintenance study Phase III HICKORY Induction and maintenance study # of patients N=350 N=800 Indication Design Induction phase: ARM A: open label etrolizumab 105mg SC q4w Maintenance study: ARM B: etrolizumab 105mg SC q4w ARM C: placebo Cohort 1 (open-label): ARM A: etrolizumab induction + placebo maintenance ARM B: etrolizumab induction + maintenance Cohort 2 (blinded): ARM A: etrolizumab induction + maintenance ARM B: placebo induction + maintenance Primary endpoint Maintenance of remission (at week 62) among randomized patients in remission at Week 10 as determined by the Mayo Clinic Score (MCS) Clinical Remission (Mayo Clinic Score, MCS) at Week 14 Remission maintenance (by MCS, at Week 66) among patients with remission at Week 14 Status FPI Q3 2014 FPI Q2 2014 UC=ulcerative colitis 121 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase/study Phase II SPRUCE Open label extension study Phase III COTTONWOOD Open label extension study # of patients N=116 N=2,600 Design Patients who were enrolled in EUCALYPTUS study and meet enrollment criteria will receive etrolizumab 105 sc q4w Primary endpoint Safety Status Recruitment completed Patients who were previously enrolled in etrolizumab phase III studies and meet enrollment criteria will receive etrolizumab 105 sc q4w Long-term efficacy as determined by partial Mayo Clinic Score (pMCS) Incidence of adverse events FPI Q3 2014 122 HCV: Danoprevir (RG7227) IFN-based triple regimen for treatment-naïve patients of Asian origin conducted in China Treatment-naïve patients of Asian origin with chronic hepatitis C genotype 1 with or without cirrhosis Indication Phase/study Phase II DAPSANG # of patients N=61 Design Primary endpoint Status In collaboration with Ascletis Without cirrhosis: ARM A: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 12 weeks With compensated cirrhosis: ARM B: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks Safety: Recruitment completed Q4 2013 Study ongoing 123 Lampalizumab (RG7417) Antibody fragment to selectively block activation of alternative complement pathway Indication Geographic atrophy (GA) secondary to age-related macular degeneration Phase/study Phase III CHROMA Phase III SPECTRI Phase II # of patients N=936 N=936 N=100 Design Primary endpoint Status ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo Primary: change in GA area Primary: change in GA area Change in GA area Secondary: change in BCVA and in Secondary: change in BCVA and in additional measures of visual additional measures of visual function function FPI Q3 2014 Design presented at EURETINA 2014 Fast track designation received Q4 2014 EURETINA=European Society of Retina Specialists ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo FPI Q3 2014 Design presented at EURETINA 2014 Fast track designation received Q4 2014 ARM A: lampalizumab 10mg q2w ARM B: lampalizumab 10mg q4w ARM C: placebo FPI Q4 2014 124 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Severe uncontrolled adult asthma Adult patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication Indication Phase/study # of patients Design Phase III LAVOLTA I Phase III LAVOLTA II N=1,050 N=1,050 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level Primary endpoint Rate of asthma exacerbations during the 52-week placebo-controlled period Rate of asthma exacerbations during the 52-week placebo-controlled period Status Enrollment completed Q4 2014 Expect data in 2016 Enrollment completed Q4 2014 Expect data in 2016 125 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Adolescent patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication Idiopathic pulmonary fibrosis Phase/study Phase III ACOUSTICS Phase II RIFF # of patients N=375 N=250 Indication Design Primary endpoint Rate of asthma exacerbations during the 52week placebo-controlled period Progression-free survival Status FPI Q3 2013 FPI Q4 2013 Subcutaneous lebrikizumab q4w on top of SOC ARM A: lebrikizumab SC q4w for 52 weeks with 52 week double-blind active ARM B: placebo treatment extension ARM A: lebrikizumab high dose, week 1-104 or week 52-104 ARM B: lebrikizumab low dose, week 1-104 or week 52-104 ARM C: placebo, week 1-52 SOC=Standard of Care; OCS=Oral Corticosteroids 126 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Adult asthma Adult asthma mild-to-moderate patients Phase/study Phase II VOCALS Phase III STRETTO # of patients N=225 N=300 Indication Design ARM A: lebrikizumab high dose SC ARM A: lebrikizumab SC q4w q4w ARM B: placebo ARM B: lebrikizumab low dose SC q4w ARM C: Montelukast ARM C: placebo Relative change in OCS dose at week 44 Absolute change in FEV1 at week 12 FPI Q1 2014 FPI Q2 2014 Primary endpoint Status 127 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Adult asthma Moderate-to-severe atopic dermatitis Phase/study Phase II CLAVIER Mechanistic biomarker study Phase II # of patients N=120 N=300 Indication Design ARM A: lebrikizumab SC q4w ARM B: placebo ARM A: lebrikizumab dose 1 ARM B: lebrikizumab dose 2 ARM C: lebrikizumab dose 3 ARM D: placebo Relative change in airway inflammation (eosinophils/mm2) at week 12 Percentage of patients achieving a 50% reduction in Eczema Area and Severity Index (EASI) score (EASI-50) from baseline to week 12 FPI Q1 2014 Expect FPI Q1 2015 Primary endpoint Status 128 Ocrelizumab (RG1594) 2nd generation anti-CD20 monoclonal antibody Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) Phase/study Phase III OPERA I Phase III OPERA II Phase III ORATORIO # of patients N=800 N=800 N=630 Design Primary endpoint Annualized relapse rate at 96 weeks versus Rebif Annualized relapse rate at 96 weeks versus Rebif Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS) Status enrollment completed Q1 2013 Expect data in 2015 enrollment completed Q1 2013 Expect data in 2015 enrollment completed Q1 2013 Expect data in 2015 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 120-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv every 24 weeks ARM B: Placebo 129 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 130 Oncology development programmes Small molecules Molecule MDM2 (4) antagonist (RG7388) MDM2 (4) ant. IV prodrug (RG7775) LSD1 inhibitor (RG6016) Raf/MEK inhibitor (RG7304, CKI27) Indication Acute myeloid leukemia Advanced cancers including AML Acute Leukemia Solid tumors Phase Phase I Phase I Phase I Phase I # of patients N=100 N=90 N=30 N=52 Design Multiple ascending dose-escalation study Dose-escalation study ARM A: patients with advanced solid tumors ARM B: patients with r/r AML Primary endpoint MTD Status FPI Q1 2013 Data presented at ASH 2014 Collaborator ASCO=American Society of Clinical Oncology Multiple ascending dose-escalation study Dose-escalation to MTD MTD MTD MTD and tumor assessment FPI Q2 2014 FPI Q1 2014 Initiated Q4 2008 enrollment stopped in Q4 2010 Oryzon Genomics, S.A. Chugai 131 Oncology development programmes Monoclonal antibodies Anti-glypican-3 MAb (RG7686, GC33) Molecule Metastatic liver cancer (hepatocellular carcinoma) 2L metastatic liver cancer (hepatocellular carcinoma) Phase Phase Ib Phase II # of patients N= 40-50 N=185 Indication Design Study US monotherapy Study Japan monotherapy Dose escalation study in combo with SOC Adaptive design study Double blind randomized 2:1 RG7686 : placebo Patients are stratified according to the level of GPC-3 expression in tumor Progression-free survival Primary endpoint Safety and tolerability Status Recruitment completed Q4 2013 Recruitment completed Q1 2013 Dose escalation completed for US and Japan monotherapy Results under internal review and combination therapy studies Collaborator SOC=standard of care Chugai 132 Oncology development programmes Monoclonal antibodies (continued) GE-huMAb HER3 (RG7116) Molecule Ang2-VEGF MAb (RG7221) Solid tumors HER2-low and HER3positive metastatic breast cancer 1L mNSCLC of squamous histology Solid tumors Metastatic colorectal cancer Phase Phase I Phase I Phase Ib/II Phase I Phase II McCAVE # of patients N=105 N=40 N=53 N≈80 N=140 Indication Design Primary endpoint Safety, PK Status FPI Q4 2011 FPI Q3 2013 Initial data presented at ASCO 2013 Multiple ascending Multiple ascending dose study with dose of RG7116 in extension cohorts and combination with imaging sub-study Perjeta and paclitaxel Combination arms with HER1-targeted therapies (erlotinib, cetuximab) Safety ASCO=American Society of Clinical Oncology ARM A: Induction: Avastin+mFOLFOX-6; followed by maintenance: Avastin+5-FU/LV ARM B: Induction: RG7221+mFOLFOX-6; followed by maintenance: RG7221+5-FU/LV RG7116 in combination Multiple ascending with carboplatin and dose study with paclitaxel extension cohorts in solid tumors to assess the PD effects and platinum-resistant ovarian cancer Safety, ORR Safety, PK PFS FPI Q4 2014 FPI Q4 2012 Dose escalation data presented at ASCO 2014 FPI Q2 2014 133 Oncology development programmes Monoclonal antibodies (continued) CSF-1R huMAb (RG7155) Molecule Indication Phase # of patients CEA-IL2v (RG7813) Solid tumors and PVNS Solid tumors Solid tumors Phase I/II Phase I Phase I N≈140 N=110 N~110 Design Multiple ascending dose study +/- paclitaxel with extension cohorts Primary endpoint Safety, PK, PD & Safety preliminary clinical activity Status FPI Q4 2011 Biomarker data presented at AACR 2013 and AACR 2014 Data presented at ASCO 2014 RG7155 in combination with Single and multiple dose RG7446 (anti-PDL1) escalation study with Part 1: dose escalation extension cohorts Part 2: expansion FPI January 2015 AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology Safety, PK, PD FPI Q4 2013 134 Oncology development programmes Monoclonal antibodies (continued) Molecule MSLN PEcFP (RG7787) CEA CD3 T-cell bispecific (TCB) (RG7802) CD40 iMAb (RG7876) in combination with anti-PDL1 (RG7446) Indication MSLN-positive solid tumors CEA-positive solid tumors Solid tumors Phase Phase I Phase Ia Phase I # of patients N=133 N=90 N=160 Design Primary endpoint Safety, PK, PD Safety, PK/PD, imaging Safety Status FPI Q4 2014 FPI Q4 2014 FPI Q4 2014 Part A: Single agent dose escalation Multiple ascending dose study with Part 1A: sequential administration of and extensions extension cohorts and imaging sub- RG7876 and RG7446 (anti-PDL1) Part B: Combination of RG7787 and study Part 1B: concomitant administration gemcitabine/nab-paclitaxel dose of RG7876 and RG7446 (anti-PDL1) escalation and extension Part 2: multiple doses of concomitant RG7876 and RG7446 (anti-PDL1) Part 3: study drugs schedule in specific indications per Part 2 AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology 135 Neuroscience development programmes Molecule PDE10A inhibitor (RG7203) TAAR1 agonist (RG7410) GABRA5 NAM (RG1662) mGlu5 PAM (RG7342) Indication Schizophrenia Schizophrenia Down Syndrome Schizophrenia Phase I Phase I Phase IIB CLEMATIS Phase I N=26 N= up to 40 N=180 N=93 Phase # of patients Design Multiple dose, double-blind study in schizophrenia patients Double-blind, randomized, placebo controlled, sequential multiple ascending dose study in HVs ARM A: RG7203 plus risperidone ARM B: placebo plus risperidone For 26 weeks patients will receive: ARM A: RG1662 120mg twice daily ARM B: RG1662 120mg twice daily ARM C: Placebo Single ascending dose of RG7342 Safety, tolerability, PK and food effect Primary endpoint Safety, tolerability, PK Safety and tolerability in HVs Cognition and adaptive behavior Status Study completed Results under internal review Study completed Q4 2014 Results under internal review FPI Q2 2014 NAM=Negative allosteric modulator; HV= healthy volunteer Study completed January 2015 Results under internal review 136 Neuroscience development programmes Molecule V1 receptor antagonist (RG7314) SMN2 splicing modifier (RG7800) Basimglurant (mGlu5 NAM, RG7090) Indication Autism Spinal muscular atrophy Adjunctive Treatment of Major Depressive Disorder Phase II VANILLA Phase Ib MOONFISH Phase II Marigold N=150 N=48 N=300 Phase # of patients Design Multi-center, randomized, Randomized, double-blind, 12double-blind, placebo-controlled week, placebo-controlled proof-of-concept study in multiple dose study in adult and individuals with Autism pediatric patients Spectrum Disorder (ASD) ARM A: basimglurant 0.5 mg ARM B: basimglurant 1.5 mg ARM C: matching placebo Primary endpoint Safety and efficacy Safety and tolerability Efficacy - Montgomery Asberg Depression Rating Scale Status FPI Q3 2013 FPI Q4 2014 Study completed Data in-house under review Data presented at ECNP and ACNP 2014 Collaborator PTC Therapeutics/ SMA Foundation ECNP=European College of Neuropsychopharmacology; ACNP=American College of Neuropsychopharmacology 137 Neuroscience development programmes Molecule Anti-aSynuclein (RG7935, PRX002) Monoamine oxidase type B (MAO-B) inhibitor (RG1577, EVT-302) MAb Tau-pS422 (RG7345) Indication Parkinson’s disease Alzheimer’s Disease Alzheimer’s disease Phase # of patients Phase I Phase I Phase IIb MAyflOwer RoAD Phase I N=40 N=up to 60 N=495 N=48 Design Double-blind, placebocontrolled, multiple ascending dose study of RG7935 in healthy subjects Double-blind, placebocontrolled, multiple ascending dose study of RG7935 in patients with Parkinson’s disease 52-week oral treatment ARM A: RG1577 (dose 1) ARM B: RG1577 (dose 2) ARM C: placebo Randomized, double-blind, placebo-controlled, single ascending dose study of RG7345 in healthy volunteers Primary endpoint Safety, tolerability, PK, immunogenicity Safety and tolerability Changes in ADAS-Cog at 52 weeks Safety Status FSI Q2 2014 FPI Q3 2014 Recruitment completed Q1 2014 FPI Q4 2014 Collaborator Prothena Evotec 138 Infectious diseases development programmes Molecule TLR7 agonist (RG7795) LptD antibiotic (RG7929) NME (RG7689) DBO Beta lactamase inhibitor (RG6080) Indication Chronic hepatitis B Pseudomonas infections (including MDR strains) Infectious diseases Infectious diseases Phase # of patients Phase I Phase II Phase I Phase I N=50 N=~50 N=77 N=40 Healthy volunteer study ARM A: Single ascending dose of RG7795 ARM B: Placebo Design Primary endpoint Status Patient and HV study Double-blind, randomized, placebo-controlled, singleascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers Randomized, double-blind, placebo-controlled, singleascending dose study in healthy volunteers Safety Safety, PK/PD Safety, PK/PD Safety, PK LPI Q4 2014 FPI Q4 2013 QIDP and fast track designation granted Q2 2014 FPI Q4 2014 Study completed Collaborator QIDP=Qualified Infectious Disease Product designation Polyphor Meiji and Fedora 139 Metabolic, ophthalmology and immunology development programmes Molecule GLP-1/GIP dual agonist (MAR709, RG7697) Aldosterone synthase inhibitor (RG7641) Anti-VEGF/Ang2 (RG7716) NME (RG7625) Indication Type 2 diabetes Metabolic diseases Wet age-related macular degeneration Autoimmune diseases Phase II Phase I Phase I Phase I N=105 N=96 N=12 N=16 ARM A: RG7641 single dose ARM B: Placebo Patient study Single ascending and multiple dose of RG7716 Phase/study # of patients Design ARM A: RG7697 SC AMR B: Liraglutide ARM C: Placebo Primary Endpoint HbA1c Safety Status FPI Q3 2014 Recruitment completed Q2 2014 Collaborator Single ascending dose of RG7625 in healthy volunteers Safety and PK Safety, PK, PD Enrollment completed Q4 2014 FPI Q4 2014 Marcadia Biotech, Inc. acquisition 140 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 141 Oncology development programmes Monoclonal antibodies 1cobimetinib Molecule Duligotuzumab (Anti-HER3 EGFR DAF MAb, RG7597) Anti-OX40 (RG7888, MOXR0916) Indication Locally advanced or metastatic tumors with mutant KRAS Solid tumors Phase/study Phase I Phase I # of patients N=50 N=400 Design Dose finding of duligotuzumab plus cobimetinib1 Primary endpoint Safety Safety Status FPI Q4 2013 FPI Q3 2014 in collaboration with Exelixis RG7888 dose escalation and expansion study 142 Oncology development programmes Antibody drug conjugates Antibody drug conjugates (ADCs) Molecule Anti-STEAP1 ADC (RG7450) NME ADC (RG7882) NME ADC (RG7841) Indication Prostate cancer Pt. resistant ovarian cancer or unresectable pancreatic cancer Refractory solid tumors Phase I Phase I Phase I N=93 N=75 N=115 Phase # of patients Design Dose escalation and expansion study Dose escalation study Dose escalation study Primary endpoint Safety Status Collaborator Dose escalation study: enrollment completed Q1 2014 Expansion study: FPI Q3 2014 Data presented at ASCO 2013-2014 and AACR 2014 Safety/PK Safety FPI Q2 2014 FPI Q2 2014 Seattle Genetics and Agensys ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research Seattle Genetics 143 Oncology development programmes Antibody drug conjugates (continued) Antibody drug conjugates (ADCs) Lifastuzumab vedotin (anti-NaPi2b ADC, RG7599) Molecule Indication NSCLC and ovarian cancer Phase # of patients Platinum-sensitive ovarian cancer Platinum-resistant ovarian cancer and NSCLC Phase I Phase Ib Phase II HERAEA N=96 N=54 N=92 Design Dose escalation study Dose escalation of RG7599 in combination with carboplatin, with or without Avastin ARM A: RG7599 ARM B: Pegylated liposomal doxorubicin Primary endpoint Safety Safety, PK Progression-free survival Status FPI Q2 2011 Data presented at ASCO 2014 FPI Q4 2013 FPI Q1 2014 Collaborator ASCO=American Society of Clinical Oncology Seattle Genetics 144 Oncology development programmes Small molecules Ipatasertib (AKT inhibitor, GDC-0068, RG7440) Molecule Indication Phase # of patients Design Primary endpoint Status 2L castration-resistant prostate cancer 1L metastatic gastric or gastroesophageal junction adenocarcinoma 1L triple-negative breast cancer Phase II A.MARTIN Phase II JAGUAR Phase II LOTUS N=262 N=153 N=120 ARM A: ipatasertib (400mg) + abiraterone ARM B: ipatasertib (200mg) + abiraterone ARM C: placebo + abiraterone ARM A: ipatasertib + mFOLFOX6 ARM B: placebo + mFOLFOX6 ARM A: ipatasertib + paclitaxel ARM B: placebo + paclitaxel Progression-free survival Progression-free survival Progression-free survival Enrollment completed Q4 2014 Enrollment completed Q4 2014 FPI Q3 2014 Collaborator mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) Array BioPharma 145 Oncology development programmes Small molecules (continued) Ipatasertib (AKT inhibitor, GDC-0068, RG7440) Molecule Indication Phase # of patients Solid tumors Neoadjuvant TNBC Phase Ib Phase II FAIRLANE N=120 N=150 Design Dose escalation with: ARM A: docetaxel ARM B: fuoropyrimidine plus oxaliplatin ARM C: paclitaxel ARM D: enzalutamide ARM A: ipatasertib + paclitaxel ARM B: placepbo + paclitaxel Primary endpoint Safety Pathalogic Complete Response Status FPI Q3 2011 Data presented at ESMO and SABCS 2014 FPI Q1 2015 Collaborator Array BioPharma ESMO=European Society for Medical Oncology; SABCS=San Antonio Breast Cancer Symposium 146 Oncology development programmes Small molecules (continued) Molecule Indoleamine 2, 3dioxygenase (IDO) Inhibitor (GDC-0919, NLG919) ChK1 inhibitor (RG7741,GDC-0575) ERK inhibitor (RG7842, GDC-0994) Indication Solid tumors Solid tumors or lymphoma Solid tumors Phase I Phase I Phase I N=36 N=170 N=78 Phase # of patients Design Primary endpoint Status Collaborator Dose escalation and expansion study Stage 1: Dose escalation Stage 2: Cohort expansion Stage 1: Dose escalation Stage 2: Cohort expansion Safety Safety/PK Safety, MTD, PK FPI Q1 2014 FPI Q2 2012 FPI Q2 2013 NewLink Genetics Array BioPharma 147 Oncology development programmes Small molecules (continued) Molecule Selective estrogen receptor degrader (SERD) (GDC-0810/ARN-810, RG6046) Selective estrogen receptor degrader (SERD(2)) (GDC-0927/SRN-927, RG6047) Indication Metastatic ER+ HER2- breast cancer Metastatic ER+ HER2- breast cancer Phase I/IIa Phase I N=141 N=90 Phase # of patients Design Phase I: dose escalation Phase IIa: dose expansion Dose escalation study Primary endpoint Safety, PK, MTD Safety Status FPI Q4 2014 FPI Q4 2015 Collaborator Seragon acquisition 148 Neuroscience development programmes Molecule Crenezumab (RG7412) Indication Alzheimer’s Disease Phase/study Phase II ABBY Cognition study Phase II BLAZE Biomarker study # of patients N=446 N=91 Design ARM A: Crenezumab sc ARM B: Crenezumab iv ARM C: Placebo Primary endpoint Change in cognition (ADAS-cog) and Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score from baseline to week 73 Status Collaborator ARM A: Crenezumab sc ARM B: Crenezumab iv ARM C: Placebo Change in brain amyloid load from baseline to week 69 enrollment completed Q3 2012 enrollment completed Q3 2012 Positive trend in cognition was observed in ARM Cognition data presented at AAIC 2014 B for people with milder disease Exploratory amyloid PET analysis suggests Data presented at AAIC 2014 reduced amyloid accumulation in ARM B Biomarker data presented at CTAD 2014 AC Immune AAIC=Alzheimer’s Association International Conference; CTAD=Clinical Trials on Alzheimer’s Disease 149 Neuroscience development programmes Crenezumab (RG7412) Molecule Nav1.7 (RG7893, GDC-0276) Mild to Moderate Alzheimer's disease Alzheimer’s Prevention Initiative (API) Colombia Pain Phase/study Phase I Phase II Cognition study Phase I # of patients N=24 N=300 N=74 Indication Design ARM A: crenezumab dose level 1 ARM B: placebo dose level 1 ARM C: crenezumab dose level 2 ARM D: placebo dose level 2 Primary endpoint Safety (incidence and nature of MRI Change on Alzheimer's Prevention safety findings) Initiative (API) Composite Cognitive Test total score Safety, tolerability, and pharmacokinetics of single and multiple doses Status Expect FPI Q1 2015 FPI Q3 2014 Collaborator AC Immune ARM A: 100 carriers receive Phase 1, randomized, placebocrenezumab sc controlled, double blinded study to ARM B: 100 carriers receive placebo determine safety, tolerability, and ARM C: 100 non-carriers receive pharmacokinetics in healthy placebo volunteers FPI Q4 2013 AC Immune and Banner Alzheimer’s Institute Xenon Pharmaceuticals Inc. 150 Immunology and infectious diseases development programmes Molecule NME (RG7880) Anti-Flu A (RG7745) Indication Inflammatory diseases Influenza Phase/study Phase I Phase IIa Phase IIb # of patients N=74 N=100 N~300 Design • Healthy volunteer study Healthy volunteers in an influenza challenge model ARM A: RG7745 ARM B: placebo ARM C: Tamiflu Primary endpoint • Safety and tolerability Status • FPI Q4 2014 Reduction in viral activity Hospitalized patients requiring oxygen with severe influenza A ARM A: RG7745 + Tamiflu ARM B: placebo + Tamiflu Safety and efficacy (time to normalization of respiratory function) Data positive with 98% reduction FPI expected Q1 2015 of viral load at 3600mg dose Presented at ISIRV 2014 ISIRV=International Society for Influenza and other Respiratory Virus Diseases 151 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 152 2014: One-off items 2014 CHFm Sale of filgrastim rights (2014) Group Pharma +428 2013 Dia Corporate Group Pharma +121 +121 Past service income (2013) +302 +131 340B reserves release (2013) +145 +145 +568 +397 +428 Corporate +428 Op. profit related to filgrastim revenue (2013) Core operating profit Dia +428 Income taxes -93 -144 Net income +335 +424 +67 +104 +67 +104 153 Geographical sales split by divisions and Group* CHFm 2014 2013 % change CER Pharmaceuticals Division 36,696 36,304 +4 15,822 15,097 +6 Europe 9,422 9,254 +3 Japan 3,301 3,405 +7 International 8,151 8,548 +2 10,766 10,476 +6 United States 2,401 2,331 +4 Europe 4,131 4,077 +2 449 492 0 3,785 3,576 +13 47,462 46,780 +5 United States 18,223 17,428 +6 Europe 13,553 13,331 +3 Japan 3,750 3,897 +6 11,936 12,124 +6 United States Diagnostics Division Japan International Group International * Geographical sales split shown here does not represent operational organization; CER=Constant Exchange Rates 154 Pharma Division sales 2014 (vs. 2013) Top 20 products Global CHFm MabThera/Rituxan Avastin Herceptin Lucentis Tarceva Actemra/RoActemra Pegasys Xolair Tamiflu Perjeta CellCept Xeloda Activase/TNKase Valcyte/Cymevene Pulmozyme Kadcyla NeoRec./Epogin Mircera Zelboraf Madopar 6,900 6,417 6,275 1,701 1,292 1,224 1,015 975 959 918 811 776 747 726 597 536 460 417 301 292 CER=Constant Exchange Rates * over +500% % CER 2 6 7 2 -1 23 -20 25 54 189 -4 -46 11 7 7 135 -8 5 -12 -3 US CHFm 3,334 2,682 1,967 1,701 641 406 194 975 686 540 195 185 698 386 386 282 69 - % CER 1 6 12 2 7 31 -36 25 62 150 -3 -70 11 9 10 29 -44 - Europe CHFm 2,014 1,958 2,234 303 433 236 74 238 216 92 182 122 176 189 101 188 106 % CER 6 3 3 -11 22 -33 292 253 -8 -70 6 -1 * -12 -1 -3 -4 Japan CHFm 226 711 270 99 214 60 113 79 57 90 0 35 57 195 17 % CER 0 9 1 10 19 28 18 281 -9 -8 -37 0 -3 International CHFm 1,326 1,066 1,804 249 171 525 86 61 343 409 49 158 89 43 214 121 44 169 % CER -1 12 8 -10 14 -8 7 326 -1 -9 13 5 5 * 12 18 41 -1 155 Pharma Division sales 2014 (vs. 2013) Recently launched products Global CHFm Erivedge % CER US CHFm % CER Europe CHFm % CER Japan CHFm % CER International CHFm % CER 128 75 83 27 39 399 - - 6 * Gazyva 49 * 43 * 5 - - - 1 - Esbriet 44 - 5 - 36 - - - 3 - CER=Constant Exchange Rates * over +500% 156 Pharma Division CER sales growth1 in % Global top 20 products MabThera/Rituxan Avastin Herceptin Lucentis Tarceva Actemra/RoActemra Pegasys Xolair Tamiflu Perjeta CellCept Xeloda Activase/TNKase Valcyte/Cymevene Pulmozyme Kadcyla NeoRec./Epogin Mircera Zelboraf Madopar Q4/13 Q1/14 Q2/14 Q3/14 Q4/14 7 13 7 22 4 23 -20 17 -27 394 -10 -3 19 26 18 -14 23 26 9 3 9 3 8 -5 23 -19 15 9 274 -1 -19 -1 12 3 474 -9 21 -2 -20 5 4 9 4 3 21 -10 22 -36 277 -11 -50 26 12 8 105 -8 2 -9 3 1 6 9 2 0 28 -22 33 121 227 0 -61 19 19 13 103 -12 -1 -13 -6 -1 7 7 -5 -2 20 -29 29 129 103 -4 -56 5 -9 4 110 -1 0 -24 13 CER=Constant Exchange Rates 1 Q4/13 vs. Q4/12; Q1-Q4/14 vs. Q1-Q4/13 157 Pharma Division CER sales growth1 in % Top 20 products by region Q1 MabThera/Rituxan Avastin Herceptin Lucentis Tarceva Actemra/RoActemra Pegasys Xolair Tamiflu Perjeta CellCept Xeloda Activase/TNKase Valcyte/Cymevene Pulmozyme Kadcyla NeoRec./Epogin Mircera Zelboraf Madopar -2 6 4 8 -6 22 -40 15 -9 161 -7 -15 0 26 2 315 -40 - CER=Constant Exchange Rates 1 Q1-Q4/14 vs. Q1-Q4/13 US Q2 Q3 8 6 17 4 16 30 -14 22 22 205 -6 -80 27 8 10 16 -46 - -4 3 10 2 11 39 -51 33 155 202 16 -93 18 21 20 3 -38 - Q4 Q1 5 7 17 -5 9 31 -49 29 127 86 -18 -92 4 -13 9 -7 -51 - 6 8 2 -12 20 -19 * * -10 -57 5 2 -14 8 12 -9 * over 500% Europe Q2 Q3 Q4 8 2 4 -12 20 -32 -71 287 -5 -71 10 -1 * -10 -1 8 -2 4 1 4 -9 25 -38 49 228 -6 -76 22 -5 * -15 -3 -12 -5 7 3 2 -9 22 -46 -93 171 -11 -77 -9 -2 * -10 -8 -16 -2 Q1 20 27 23 42 49 16 -17 5 8 -26 36 4 Japan Q2 Q3 -17 -5 -12 6 5 45 -74 -14 -23 -45 -12 -6 5 13 5 7 21 48 238 375 -12 -6 -38 -2 -2 Q4 International Q1 Q2 Q3 Q4 -4 5 -7 -6 11 -1 190 32 -13 -8 -39 -11 -5 12 -2 9 -17 7 9 15 16 0 12 14 6 -6 -9 -13 -13 3 28 21 6 -7 3 -8 -17 -8 -44 37 350 * * 341 177 6 -16 -3 13 -3 -2 -19 -10 -4 19 27 12 -7 24 12 -1 10 9 10 -1 * * * 7 12 3 28 8 32 1 30 98 56 65 -1 -29 7 -7 24 158 CER sales growth (%) Quarterly development 2013 vs. 2012 2014 vs. 2013 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 7 4 9 7 4 4 4 5 13 7 16 5 3 8 4 10 Europe 1 2 3 2 5 1 1 4 Japan 2 2 4 2 19 -4 8 5 International 8 2 5 18 1 3 6 0 1 4 7 5 7 5 7 7 6 4 8 7 5 4 5 6 Pharmaceuticals Division United States Diagnostics Division Roche Group 159 CER=Constant Exchange Rates 2014: Oncology franchise 2014 sales of CHF 22.797bn 2014 vs. 2013 CER growth CHFbn US +9% • HER2 franchise (including strong uptake of PERJETA & Kadcyla), and Avastin (+6%) driving growth and performance +5% Europe +5% • Growth mainly driven by HER2 franchise (with strong uptake of PERJETA & Kadcyla), as well as MabThera (+6%) +5% 24.0 21.0 18.0 15.0 12.0 9.0 6.0 +3% 3.0 International • Continued strong growth for Avastin (+12%) and Herceptin (+8%) 0.0 2012 US Europe 2013 International 2014 Japan Japan • Growth driven largely by Avastin (+9%) 160 CER=Constant Exchange Rates MabThera/Rituxan Global sales CHFbn CER growth +2% 8.0 Regional sales CER growth US +1% Europe +6% 7.0 6.0 5.0 4.0 Japan 0% 3.0 International 2.0 -1% 1.0 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 6.900bn • Europe: Growth driven by increased market share in follicular lymphoma, as well as CLL (1L) • US: Sales stable but comparison distorted by 340B baseline effect (+5% excl. base effect) • International: Growth impacted by economic conditions in Russia but demand remained strong in Latin America 161 CER=Constant Exchange Rates Avastin Global sales CHFbn CER growth +6% Regional sales CER growth US +6% Europe +3% 3.0 Japan +9% 2.0 International 7.0 6.0 5.0 4.0 +12% 1.0 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 6.417bn • Europe: Growth driven by further uptake in ovarian and strong demand across other indications • US: Sales driven by growing demand in colorectal, cervical and ovarian cancer • Japan: Driven by higher sales in breast cancer, as well as ovarian cancer and malignant glioma • International: Strong growth driven by launches in a number of markets for ovarian cancer treatment, as well as by demand in colorectal cancer 162 CER=Constant Exchange Rates HER2 Franchise (Herceptin, Perjeta, Kadcyla) Global sales CHFbn CER growth +20% Regional sales CER growth US +27% Europe +18% 3.0 Japan +33% 2.0 International +13% 9.0 8.0 7.0 6.0 5.0 4.0 1.0 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 7.729bn • Strong growth driven by continued uptake of PERJETA in 1/2L mBC and in the neoadjuvant setting, (particularly US), as well as by Kadcyla in 2L mBC • Continued strong growth in Herceptin benefiting from higher volumes / prolonged treatment times 163 CER=Constant Exchange Rates Herceptin Global sales CHFbn CER growth +7% 7.0 Regional sales CER growth US +12% 6.0 5.0 Europe +3% Japan +1% International +8% 4.0 3.0 2.0 1.0 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 6.275bn • US: Continued growth in mBC (1L) • Europe: Strong demand in Germany; subcutaneous formulation now available in many markets • Japan: Increased usage in combination with PERJETA • International: Strong growth in Latin America driven by access in public markets, as well as Asia, particularly from the patient assistance program in China 164 CER=Constant Exchange Rates Perjeta Global sales CHFbn CER growth Regional sales +189% 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 US CER growth +150% Europe +253% Japan +281% International +326% 2010 2011 2012 2013 2014 2014 sales of CHF 0.918bn • Perjeta sales grew in all regions with strong uptake in the US, Germany and France – Approved in all major markets for 1L mBC (US, EU, Japan and most E7) – Neoadjuvant Indication approved in several markets – Also benefitting from impressive OS results of CLEOPATRA study 165 CER=Constant Exchange Rates Xeloda Global sales CHFbn CER growth -46% 1.6 1.4 1.2 Regional sales US CER growth -70% Europe -70% Japan -8% International -9% 1.0 0.8 0.6 0.4 0.2 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 0.776bn • Overall impact due to loss of exclusivity (LoE): – US: LoE in February 2014 – Europe: LoE in December 2013 166 CER=Constant Exchange Rates Tarceva Global sales CHFbn CER growth -1% 1.6 1.4 1.2 1.0 0.8 0.6 Regional sales CER growth US +7% Europe -11% Japan +10% International 0.4 -10% 0.2 0.0 2010 2011 2012 2013 2014 2014 sales of CHF 1.292bn • Europe: Increased demand in 1L EGFR Mut+ market offset by decline 2L EGFR WT NSCLC • Japan: Good growth following launch of 1L Mut+ NSCLC indication in Q3 2014 • International: Local competition in China 167 CER=Constant Exchange Rates 2014: Immunology franchise 2014 sales of CHF 5.087bn 2014 vs. 2013 CER growth CHFbn +13% 6.0 +5% 5.0 +4% 4.0 +11% 3.0 2.0 +19% 1.0 0.0 2012 US Europe 2013 International 2014 Japan • Overall strong demand for immunology medicines, notably in treatment of rheumatoid arthritis (RA) with Actemra (+23%) and Xolair (+25%) for chronic hives and allergic asthma Actemra/RoActemra • US, EU & Japan: Strong growth driven by increased use in monotherapy and earlier use for RA, with significant uptake of new SC formulation. EU approval for early-stage RA • International: Growth driven by strong launches in China & Turkey, and continued fast uptake in Australia & Argentina Xolair • Approved by FDA to treat a form of chronic hives in 2014, adding to its use in allergic asthma 168 CER=Constant Exchange Rates Tamiflu quarterly sales 2010 - 2014 Retail and Governments/Corporations CHFm 600 Retail Governments & Corporations 500 95 400 300 200 422 288 23 302 233 100 170 91 0 214 177 7 48 7 17 19 3 45 -6 Q4 10 Q1 11 Q2 11 Q3 11 12 46 496 277 26 10 8 15 5 Q1 12 Q2 12 Q3 12 31 Q4 12 33 44 32 1 2 7 Q2 13 Q3 13 Q4 13 67 17 70 11 10 11 Q2 14 Q3 14 Q4 14 -100 Q1 10 Q2 10 Q3 10 Q4 11 Q1 13 Q1 14 169 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 170 Diagnostics Division CER growth By Region and Business Area (vs. 2013) Global North America % CER % CER CHFm growth CHFm growth EMEA¹ % CER CHFm growth RoW % CER CHFm growth Professional Diagnostics 6,045 8 1,236 6 2,585 4 2,224 15 Diabetes Care 2,392 1 442 -6 1,475 2 475 6 Molecular Diagnostics 1,613 6 579 10 628 4 406 3 716 10 415 6 198 17 103 20 10,766 6 2,672 4 4,886 4 Tissue Diagnostics Diagnostics Division CER=Constant Exchange Rates ¹ Europe, Middle East and Africa 3,208 12 171 Diagnostics Division quarterly sales and CER growth1 Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Professional Diagnostics 1,426 9 Diabetes Care 576 3 678 Molecular Diagnostics 383 4 416 Tissue Diagnostics 159 8 2,544 7 Dia Division CER=Constant Exchange Rates ¹ versus same period of prior year 1,521 10 1,392 9 1,512 8 1,493 8 1,648 8 -4 538 5 602 -4 581 4 671 1 3 370 4 392 3 403 8 448 7 184 10 156 4 178 14 2,456 7 2,799 5 2,684 5 175 13 2,652 7 207 10 2,974 7 172 2014: Diagnostics Division sales Growth driven by Asia Pacific CHF 10,766 m CER sales growth 2,672 804 1,956 North America 25% Diagnostics Division Latin America 7% North America 4% EMEA¹ 4% Asia Pacific 19% 4,886 448 CER=Constant Exchange Rates ¹ Europe, Middle East and Africa 6% Latin America 13% Asia Pacific Japan 4% EMEA1 45% Japan 15% 0% 173 2014: Diagnostics Division sales Growth driven by Professional Diagnostics CHF 10,766 m CER sales growth 2,392 Diabetes Care 22% Diagnostics Division Diabetes Care 1,613 6,045 716 Molecular Diagnostics 15% Professional Diagnostics 7% Molecular Diagnostics Professional Diagnostics 56% Tissue Diagnostics Tissue Diagnostics 6% 1% 8% 6% 10% 174 CER=Constant Exchange Rates Professional Diagnostics Strong growth driven by Immunodiagnostics CHFbn 2014 vs. 2013 CER growth 7.0 +8% 6.0 +2% 5.0 +3% 4.0 +7% 3.0 2.0 +13% 1.0 0.0 2012 Immunodiagnostics 2013 Clinical Chemistry 2014 POC products Other 175 CER=Constant Exchange Rates Diabetes Care Adapting to a challenging market environment CHFbn 2014 vs. 2013 CER growth 2.8 +1% 2.4 +6% 2.0 1.6 +1% 1.2 0.8 0.4 0.0 2012 2013 Blood Glucose Monitoring 2014 Other 176 CER=Constant Exchange Rates Molecular Diagnostics Growth driven by Virology 2014 vs. 2013 CER growth CHFbn +6% 1.8 1.6 1.4 -2% 1.2 +16% 1.0 +4% 0.8 +6% 0.6 0.4 +7% 0.2 0.0 2012 Other Blood Screening Virology 2013 2014 HPV & Microbiology Biochem Reag & qPCR & NAP Systems 177 CER=Constant Exchange Rates Tissue Diagnostics Strong growth in EMEA¹ and North America CHFbn 2014 vs. 2013 CER growth 0.8 +10% 0.7 +23% 0.6 +9% 0.5 0.4 0.3 +9% 0.2 0.1 0.0 2012 Advanced Staining CER=Constant Exchange Rates ¹ Europe, Middle East and Africa 2013 2014 Primary Staining Other 178 2015: Key planned product launches Professional Diagnostics Product Description cobas c 513 dedicated HbA1C analyzer EU cobas t 411 core lab coagulation analyzer EU Cobas 8100 V2 integrated pre- and post-analytical solution WW CoaguChek Pro II professional system for PT and aPTT testing EU HTLV human T-lymphotropic virus diagnostics test EU Cobas h 232 Troponin T Point of Care test version of Elecsys cTNT-hs EU Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors Region 179 2015: Key planned product launches Molecular Diagnostics Product Description Region cobas® 6800/8800 medium to high volume automated real-time PCR US cobas® 6800/8800 MPX multiplex bloodscreening test US cobas® 6800/8800 HBV quantitative HBV viral load test EU cobas® 4800 HIV-1 cobas® 4800 HCV cobas® 4800 HBV quantitative HIV viral load test quantitative HCV viral load test quantitative HBV viral load test EU cobas® EGFR Test v2 detection of EGFR in plasma EU cobas® Liat Influenza A/B + RSV US POC detection Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 180 2015: Key planned product launches Tissue Diagnostics Product Description VENTANA HE 600 automated H&E staining platform Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors Region WW 181 2015: Key planned product launches Diabetes Care Product Description Accu-Chek Active no-code next-gen. bG meter, no coding of test strips WW Accu-Chek Connect bG meter with connectivity to smartphones, mobile applications and cloud US Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors Region 182 Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) Roche Group 2014 results Diagnostics Foreign exchange rate information 183 CHF / USD Monthly averages 0,99 0,97 0,95 2013 0,93 0,91 2014 0,89 0,87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages 0,99 0,97 0,95 2013 0,93 -4% 0,91 0,89 -5% -4% -1% 2014 0,87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 184 CHF / USD 0.99 0.97 monthly avg 2013 0.95 avg full year 2013 0.93 -1% avg full year 2014 0.91 0.89 monthly avg 2014 0.87 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 185 CHF / EUR Monthly averages 1,25 1,24 2013 1,23 1,22 2014 1,21 1,20 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year-To-Date averages 1,25 1,24 2013 1,23 -1% 1,22 2014 1,21 -1% 0% -1% 1,20 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 186 CHF / EUR 1.25 1.24 monthly avg 2013 1.23 avg full year 2013 -1% 1.22 avg full year 2014 1.21 monthly avg 2014 1.20 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 187 Average exchange rates YTD Dec 14 YTD Dec 13 USD 0.91 0.93 EUR 1.21 1.23 JPY 0.86 0.95 -10% YTD Dec 14 vs. YTD Dec 13 -8% -6% -4% -2% 0% 188 Exchange rate impact on sales growth In 2014 negative impact from Latin American currencies, JPY and USD Development of average exchange rates versus prior year period CHF / EUR -0.4% -0.7% -1.1% CHF / USD -4.0% -4.8% -3.9% CHF / JPY -13.9% -11.4% -9.8% Difference in CHF / CER growth -5.8%p 5.0% Sales growth 2014 vs. 2013 -5.9%p -4.9%p -3.4%p 4.9% 4.6% 4.5% -1.3% -1.3% -9.0% 1.5% CER CHF growth growth -0.8% Q1 CER=Constant Exchange Rates -1.4% HY -0.3% YTD 9 FY 189 Exchange rate impact on sales growth In 2014 negative impact from Latin American currencies, JPY and USD Development of average exchange rates versus prior year period CHF / EUR -0.4% -0.9% -1.9% CHF / USD -4.0% -5.6% -1.9% CHF / JPY -13.9% -8.9% -6.6% Difference in CHF / CER growth -5.8%p 5.0% Sales growth 2014 vs. 2013 -5.9%p +1.0%p 5.6% 6.6% 1.8% CER CHF growth growth -0.8% Q1 CER=Constant Exchange Rates -3.0%p 4.8% 4.0% -2.0% +6.7% -6.3% -1.9% Q2 Q3 Q4 190 Exchange rate impact on sales growth Negative impact from Latin American currencies, JPY and USD +4.9% -0.9%p -0.8%p -0.5%p -0.3%p CER sales growth 2014 vs. 2013 CER Lat-Am CER=Constant Exchange Rates JPY USD As-Pac -0.3%p Other Europe -0.3%p Other -0.3%p EUR +1.5% CHF sales growth 2014 vs. 2013 CHF 191 Doing now what patients need next
© Copyright 2024